```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssspta1623kxg

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  DEC 05   CASREACT(R) - Over 10 million reactions available
 NEWS  4  DEC 14   2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS  5  DEC 14   2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS  6  DEC 14   CA/CAplus to be enhanced with updated IPC codes
 NEWS  7  DEC 21   IPC search and display fields enhanced in CA/CAplus with the
                   IPC reform
 NEWS  8  DEC 23   New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                   USPAT2
 NEWS  9  JAN 13   IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS 10  JAN 13   New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                   INPADOC
 NEWS 11  JAN 17   Pre-1988 INPI data added to MARPAT
 NEWS 12  JAN 17   IPC 8 in the WPI family of databases including WPIFV

 NEWS EXPRESS  JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:23:37 ON 30 JAN 2006

=> file polymer medline biosis embase
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'APOLLIT' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (c) 2006 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH
```

FILE 'CAPLUS' ENTERED AT 09:24:02 ON 30 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (c) 2006 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 09:24:02 ON 30 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 09:24:02 ON 30 JAN 2006
Compendex Compilation and Indexing (C) 2006
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'NTIS' ENTERED AT 09:24:02 ON 30 JAN 2006
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2006)

FILE 'PASCAL' ENTERED AT 09:24:02 ON 30 JAN 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 09:24:02 ON 30 JAN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 09:24:02 ON 30 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 09:24:02 ON 30 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WSCA' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 PAINT RESEARCH

```
FILE 'WTEXTILES' ENTERED AT 09:24:02 ON 30 JAN 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'MEDLINE' ENTERED AT 09:24:02 ON 30 JAN 2006

FILE 'BIOSIS' ENTERED AT 09:24:02 ON 30 JAN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 09:24:02 ON 30 JAN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

=> s urinary(a)tract(a)infect?
  15 FILES SEARCHED...
L1      118295 URINARY(A) TRACT(A) INFECT?

=> s l1 and treat?
  17 FILES SEARCHED...
L2       42971 L1 AND TREAT?

=> s l2 and D-mannose
  22 FILES SEARCHED...
L3         142 L2 AND D-MANNOSE

=> s l3 and (crataeva or willow or pollen)
L4           5 L3 AND (CRATAEVA OR WILLOW OR POLLEN)

=> dis l4 1-5 bib abs

L4   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2004:612489  CAPLUS
DN   141:117126
TI   Method and composition for maintaining urinary tract health in the face of
     infections
IN   Oneal, Joseph; White, Gary
PA   USA
SO   U.S. Pat. Appl. Publ., 6 pp.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   US 2004147459        A1    20040729    US 2003-691423          20031022
PRAI US 2002-420696P      P     20021023
AB   The sugar mannose has been used to maintain urinary tract health in the
     face of Escherichia coli infections.  An optimal dose is disclosed to be
     of one tsp (two grams) three times a day for one to two weeks or until
     symptoms subside.  The maintenance dosage for prophylaxis is one-half tsp
     (1 g) 1 to two times per day.  Children's dosages are cut in half.  For
     women who experience UTIs after sexual relations, one tsp is taken an hour
     prior to intimate relations and an addnl. one tsp immediately afterwards.
     It is further disclosed to use any of an extract of Crataeva
     nurvala , white willow bark, and pollen extract in
     conjunction with the mannose to provide further effect.

L4   ANSWER 2 OF 5  USPATFULL on STN
AN     2005:10558  USPATFULL
TI     Multi-phase, multi-compartment capsular delivery apparatus and methods
       for using same
IN     Miller, Fred H., Tampa, FL, UNITED STATES
PI     US 2005008690      A1   20050113
AI     US 2004-804576     A1   20040319 (10)
RLI    Continuation-in-part of Ser. No. WO 2003-US10816, filed on 9 Apr 2003,
       PENDING
PRAI   US 2002-371448P     20020410 (60)
DT     Utility
FS     APPLICATION
LREP   FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
```

CLMN Number of Claims: 118
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 6126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraccutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 5 USPATFULL on STN
AN 2004:190686 USPATFULL
TI Method and composition for maintaining urinary tract health in the face of infections
IN Oneal, Joseph, Irving, TX, UNITED STATES
White, Gary, Irving, TX, UNITED STATES
PI US 2004147459 A1 20040729
AI US 2003-691423 A1 20031022 (10)
PRAI US 2002-420696P 20021023 (60)
DT Utility
FS APPLICATION
LREP CARSTENS YEE & CAHOON, LLP, P O BOX 802334, DALLAS, TX, 75380
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The sugar mannose has been used to maintain urinary tract health in the face of E. coli infections. An optimal dose is disclosed to be of one teaspoon (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophalaxis is one-half teaspoon (1 gram) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one teaspoon is taken an hour prior to intimate relations and an additional one teaspoon immediately afterwards. It is further disclosed to use any of an extract of **Crataeva** nurvala, white **willow** bark, and **pollen** extract in conjunction with the mannose to provide further effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 5 USPATFULL on STN
AN 87:56793 USPATFULL
TI Method for the **treatment** of adult respiratory distress syndrome
IN Raffin, Thomas A., Palo Alto, CA, United States
Stevens, John H., Palo Alto, CA, United States
PA The Board of Trustees of the Leland Stanford Junior University, Stanford, CA, United States (U.S. corporation)
PI US 4686100 19870811
AI US 1985-718918 19850402 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Foelak, Morton; Assistant Examiner: Draper, Garnette D.
LREP Ciotti & Murashige
CLMN Number of Claims: 8
ECL Exemplary Claim: 1,8
DRWN No Drawings

LN.CNT 489
AB A method for **treating** adult respiratory distress syndrome (ARDS) and sepsis in a patient in need thereof which comprises administering to said patient an antibody to complement component C5a or the des Arg derivative thereof in an amount effective to **treat** ARDS and sepsis.

L4 ANSWER 5 OF 5 WPINDEX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-570523 [55] WPINDEX
DNC C2004-208289
TI Use of **D-mannose** for maintenance of urinary tract health in the face of infection e.g. E. Coli infection.
DC B03 B04
IN ONEAL, J; WHITE, G
PA (ONEA-I) ONEAL J; (WHIT-I) WHITE G
CYC 1
PI US 2004147459 A1 20040729 (200455)* 6
ADT US 2004147459 A1 Provisional US 2002-420696P 20021023, US 2003-691423 20031022
PRAI US 2002-420696P 20021023; US 2003-691423 20031022
AN 2004-570523 [55] WPINDEX
AB US2004147459 A UPAB: 20040826
NOVELTY - Maintenance of urinary tract health in the face of infection involves administering a dosage of 1 - 2 teaspoons of **D-mannose** three times a day with meals for 1 - 2 weeks or until the symptoms subside.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a composition comprising a therapeutic dosage of **D-mannose** and a therapeutic dosage of at least one of an extract of **Crataeva** nurvala, **willow** bark or **pollen** extract simultaneously with **D-mannose**.

ACTIVITY - Uropathic; Antimicrobial.

MECHANISM OF ACTION - E. coli urethral epithelial cell attachment inhibitor.

USE - For maintaining urinary tract health in the face of infection; in combination with a capsule containing herbs that affect the urinary tract; and for dealing with a **urinary tract infection** (all claimed). The **urinary tract infection** include E. coli infection.

ADVANTAGE - The use of **D-mannose** in the maintenance of urinary tract health in the face of infection and in the **treatment** of **urinary tract infection** preferentially provides attachment of E. coli fimbriae to the administered **D-mannose** present in the urine, rather than attachment to **D-mannose** in the epithelial cells of the urinary tract. This results in the E. coli bacteria surrounded by the molecules of **D-mannose** and promotes their natural elimination by mechanical and not pharmacological action. The few remaining bacteria can then be better handled by the body's natural defenses, the white blood cells. Mannose can not be broken down in the body, and thus is safe for diabetics, pregnant women and the elderly, and is virtually free from the risk of overdose The method does not involve the use of antibiotics and hence avoids the side effects and resistant stain development associated with them. The administration regimen provides a quantity of mannose sufficient to remove a majority of E/ coli in the urinary tract, while improving the ease of use and compliance. The dosages are effective in doctor-run trials.

Dwg.0/3

=> s l3 and (cratavin or salicin)
L5 7 L3 AND (CRATAVIN OR SALICIN)

=> dis l5 1-7 bib abs

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:612489 CAPLUS
DN 141:117126

TI Method and composition for maintaining urinary tract health in the face of infections
IN Oneal, Joseph; White, Gary
PA USA
SO U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala , white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

L5 ANSWER 2 OF 7 USPATFULL on STN
AN 2005:10558 USPATFULL
TI Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
IN Miller, Fred H., Tampa, FL, UNITED STATES
PI US 2005008690 A1 20050113
AI US 2004-804576 A1 20040319 (10)
RLI Continuation-in-part of Ser. No. WO 2003-US10816, filed on 9 Apr 2003, PENDING
PRAI US 2002-371448P 20020410 (60)
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
CLMN Number of Claims: 118
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 6126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multi-compartment capsule, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraccutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 7 USPATFULL on STN
AN 2004:190686 USPATFULL
TI Method and composition for maintaining urinary tract health in the face of infections
IN Oneal, Joseph, Irving, TX, UNITED STATES
White, Gary, Irving, TX, UNITED STATES
PI US 2004147459 A1 20040729
AI US 2003-691423 A1 20031022 (10)
PRAI US 2002-420696P 20021023 (60)
DT Utility
FS APPLICATION
LREP CARSTENS YEE & CAHOON, LLP, P O BOX 802334, DALLAS, TX, 75380

CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The sugar mannose has been used to maintain urinary tract health in the face of E. coli infections. An optimal dose is disclosed to be of one teaspoon (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophalaxis is one-half teaspoon (1 gram) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one teaspoon is taken an hour prior to intimate relations and an additional one teaspoon immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala, white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 7 USPATFULL on STN
AN 2004:82309 USPATFULL
TI Combination of probiotics
IN Mayra-Makinen, Annika, Helsinki, FINLAND
Suomalainen, Tarja, Helsinki, FINLAND
Vaarala, Outi, Helsinki, FINLAND
PI US 2004062758 A1 20040401
AI US 2003-470151 A1 20031022 (10)
WO 2002-FI35 20020117
PRAI FI 2001-157 20010125
DT Utility
FS APPLICATION
LREP Nixon & Vanderhye, 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 827
AB The invention relates to a probiotic combination comprising different combinations of lactobacilli. propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.

L5 ANSWER 5 OF 7 USPATFULL on STN
AN 81:67074 USPATFULL
TI Allylic methyl-hydroxylated novobiocins
IN Sebek, Oldrich K., Kalamazoo, MI, United States
Dolak, Lester A., Cooper Township Kalamazoo County, MI, United States
PA The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI US 4304855 19811208
AI US 1977-793784 19770505 (5)
DT Utility
FS Granted
EXNAM Primary Examiner: Hruskoci, Peter A.
LREP Stein, Bruce
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 680
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a fermentation process for producing allylic methyl-hydroxylated novobiocin and derivatives thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 7 USPATFULL on STN
AN 79:18080 USPATFULL

```
TI     Allylic methyl-hydroxylated novobiocins
IN     Sebek, Oldrich K., Kalamazoo, MI, United States
       Dolak, Lester A., Cooper Township, Kalamazoo County, MI, United States
PA     The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI     US 4148992              19790410
AI     US 1978-878115          19780215 (5)
RLI    Division of Ser. No. US 1977-793784, filed on 5 May 1977, now Defensive
       Publication No.
DT     Utility
FS     Granted
EXNAM  Primary Examiner: Brown, Johnnie R.
LREP   Stein, Bruce
CLMN   Number of Claims: 9
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to a fermentation process for producing
       allylic methyl-hydroxylated novobiocin and derivatives thereof. These
       hydroxy novobiocins (II) are useful as antibiotics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 7 OF 7  USPATFULL on STN
AN     78:66969  USPATFULL
TI     Allylic methyl-hydroxylated novobiocins
IN     Sebek, Oldrich K., Kalamazoo, MI, United States
       Dolak, Lester A., Kalamazoo, MI, United States
PA     The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)
PI     US 4128563              19781205
AI     US 1978-878114          19780215 (5)
RLI    Division of Ser. No. US 1977-793784, filed on 5 May 1977, now Defensive
       Publication No.
DT     Utility
FS     Granted
EXNAM  Primary Examiner: Trousof, Natalie; Assistant Examiner: Fan, Jane T.
LREP   Stein, Bruce
CLMN   Number of Claims: 5
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 648
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to a fermentation process for producing
       allylic methyl-hydroxylated novobiocin and derivatives thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s l3 and (capsule or powder)
  22 FILES SEARCHED...
L6          86 L3 AND (CAPSULE OR POWDER)

=> s l3 and lupeol
L7           1 L3 AND LUPEOL

=> dis l7 bib abs

L7   ANSWER 1 OF 1  USPATFULL on STN
AN     2004:190686  USPATFULL
TI     Method and composition for maintaining urinary tract health in the face
       of infections
IN     Oneal, Joseph, Irving, TX, UNITED STATES
       White, Gary, Irving, TX, UNITED STATES
PI     US 2004147459      A1   20040729
AI     US 2003-691423     A1   20031022 (10)
PRAI   US 2002-420696P     20021023 (60)
DT     Utility
FS     APPLICATION
LREP   CARSTENS YEE & CAHOON, LLP, P O BOX 802334, DALLAS, TX, 75380
```

CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The sugar mannose has been used to maintain urinary tract health in the face of E. coli infections. An optimal dose is disclosed to be of one teaspoon (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophalaxis is one-half teaspoon (1 gram) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one teaspoon is taken an hour prior to intimate relations and an additional one teaspoon immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala, white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> dis l6 1-86 bib abs

L6 ANSWER 1 OF 86 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:612489 CAPLUS
DN 141:117126
TI Method and composition for maintaining urinary tract health in the face of infections
IN Oneal, Joseph; White, Gary
PA USA
SO U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala , white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

L6 ANSWER 2 OF 86 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:543349 CAPLUS
DN 141:94307
TI Compositions comprising plant extracts and sugar for use in inhibiting bacterial proliferation
IN Clayton, Paul; Conn, Helen
PA Forum Bioscience Holdings Limited, UK
SO Brit. UK Pat. Appl., 17 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI GB 2396811	A1	20040707	GB 2003-29467	20031219
WO 2004056380	A2	20040708	WO 2003-GB5578	20031219
WO 2004056380	A3	20040916		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,

NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRAI GB 2002-30042 A 20021223
AB Claimed is a composition comprising an extract from a plant that is a member of Ericaceae, Rosaceae, Pinaceae, or Vitaceae family and at least one sugar that is not metabolized or is only partly metabolized by the body. The sugar is preferably a monosaccharide, such as L-arabinose, L-fucose, **D-mannose**, L-rhamnose, L-xylose, lyxose or galactose. A preferred composition comprises an extract of cranberry with **D-mannose**. These compns. may be used to **treat** bacterial infection caused by E. coli, particularly **urinary tract infections**. Compns. comprising an anthocyanidin or a proanthocyanidin and at least one sugar that is not metabolized or is only partly metabolized by the human or animal body are also described.
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 86 USPATFULL on STN
AN 2006:15872 USPATFULL
TI Albumin fusion proteins
IN Haseltine, William A., Washington, DC, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 2006014254 A1 20060119
AI US 2005-175690 A1 20050707 (11)
RLI Continuation of Ser. No. WO 2004-US1369, filed on 20 Jan 2004, PENDING
PRAI US 2003-441305P 20030122 (60)
US 2003-453201P 20030311 (60)
US 2003-467222P 20030502 (60)
US 2003-472816P 20030523 (60)
US 2003-476267P 20030606 (60)
US 2003-505172P 20030924 (60)
US 2003-506746P 20030930 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 17653
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

L6 ANSWER 4 OF 86 USPATFULL on STN
AN 2005:330573 USPATFULL
TI Carbohydrate encapsulated nanoparticle based affinity mass spectrometry
IN Lin, Chun-Cheng, Fongyuan City, TAIWAN, PROVINCE OF CHINA
Chen, Yu-Ju, Lugang Township, TAIWAN, PROVINCE OF CHINA
PA Academia Sinica, Office of Public Affairs (Technology Transfer), Taipei, TAIWAN, PROVINCE OF CHINA (non-U.S. corporation)
PI US 2005287552 A1 20051229
AI US 2005-91649 A1 20050328 (11)
RLI Continuation-in-part of Ser. No. US 2004-782076, filed on 19 Feb 2004, PENDING

PRAI US 2003-448716P 20030219 (60)
DT Utility
FS APPLICATION
LREP Jason R. Bond, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 2470
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods and compositions for carbohydrate encapsulated nanoparticle based mass spectrometry. For example, the present invention provides methods of screening samples for carbohydrate binding molecules, methods of characterizing carbohydrate binding epitopes in target molecules, and MALDI matrix compositions comprising carbohydrate encapsulated nanoparticles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 86 USPATFULL on STN
AN 2005:305894 USPATFULL
TI Albumin fusion proteins
IN Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
Delta Biotechnology Limited (U.S. corporation)
PI US 2005266533 A1 20051201
AI US 2005-78914 A1 20050314 (11)
RLI Continuation of Ser. No. US 2001-832501, filed on 12 Apr 2001, ABANDONED
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-60
DRWN 20 Drawing Page(s)
LN.CNT 13941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 86 USPATFULL on STN
AN 2005:305893 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
Principia Pharmaceutical Corporation (U.S. corporation)
PI US 2005266532 A1 20051201
AI US 2005-78663 A1 20050314 (11)
RLI Continuation of Ser. No. US 2001-833117, filed on 12 Apr 2001, ABANDONED

PRAI US 2000-229358P 20000412 (60)
US 2000-199384P 20000425 (60)
US 2000-256931P 20001221 (60)
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1-59
DRWN 20 Drawing Page(s)
LN.CNT 12894
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 86 USPATFULL on STN
AN 2005:280980 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2005244931 A1 20051103
AI US 2004-967457 A1 20041019 (10)
RLI Division of Ser. No. US 2001-833041, filed on 12 Apr 2001, PENDING
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1-33
DRWN 20 Drawing Page(s)
LN.CNT 16289
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 86 USPATFULL on STN
AN 2005:274503 USPATFULL
TI 67 human secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Florence, Kimberly, Rockville, MD, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES

Endress, Gregory A., Florence, MA, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
Birse, Charles, North Potomac, MD, UNITED STATES
PI US 2005239059 A1 20051027
AI US 2001-949925 A1 20010912 (9)
RLI Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999, PENDING Continuation-in-part of Ser. No. US 1999-363044, filed on 29 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999, PENDING
PRAI US 2000-232150P 20000912 (60)
US 1998-73170P 19980130 (60)
US 1998-73167P 19980130 (60)
US 1998-73165P 19980130 (60)
US 1998-73164P 19980130 (60)
US 1998-73162P 19980130 (60)
US 1998-73161P 19980130 (60)
US 1998-73160P 19980130 (60)
US 1998-73159P 19980130 (60)
US 1998-73170P 19980130 (60)
US 1998-73167P 19980130 (60)
US 1998-73165P 19980130 (60)
US 1998-73164P 19980130 (60)
US 1998-73162P 19980130 (60)
US 1998-73161P 19980130 (60)
US 1998-73160P 19980130 (60)
US 1998-73159P 19980130 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 21427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and **treating** diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 86 USPATFULL on STN
AN 2005:268651 USPATFULL
TI Antibacterial compounds and methods for **treating** gram positive bacterial infections
IN McCafferty, Dewey G., Plymouth Meeting, PA, UNITED STATES
PA The Trustees of the University of Pennslyvania, Philadelphia, PA, UNITED STATES (U.S. corporation)
PI US 2005233971 A1 20051020
AI US 2003-516012 A1 20030602 (10)
WO 2003-US17215 20030602
20041129 PCT 371 date
PRAI US 2003-385038P 20020531 (60)
DT Utility
FS APPLICATION
LREP NATH & ASSOCIATES, 1030 15th STREET, NW, 6TH FLOOR, WASHINGTON, DC, 20005, US
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 1960
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present inventive subject matter relates to novel antibacterial

compounds that are capable of inhibiting bacterial multiplication and killing living bacteria. The present inventive subject matter further relates to methods for **treating** Gram positive bacterial infections using the inventive compounds.

##STR1##

##STR2##

	R.sub.1	R.sub.2
1	α-D-Mannosyl-(1→2)-α-**D-mannose** NH.sub.3.sup.+	
2	H	NH.sub.3.sup.+
3	α-D-Mannosyl-(1→2)-α-**D-mannose** HNC(NH)NH.sub.3.sup.+	
4	α-D-Mannosyl-(1→2)-α-**D-mannose** HN.sup.+(CH.sub.2).sub.2CH(CH.sub.3).sub.2	
5	α-D-Mannosyl-(1→2)-α-**D-mannose** NHAc	
6	α-D-Mannosyl-(1→2)-α-**D-mannose** NH.sub.3.sup.+ (Lactone hydrolyzed)	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 86 USPATFULL on STN
AN 2005:267622 USPATFULL
TI Recombinant DNA, plasmid, transformed microorganism and vaccine protein for prevention and therapy of **urinary tract infection**
IN Pyo, Suhk-Neung, Seoul, KOREA, REPUBLIC OF
Lee, Yong-Hwa, Seoul, KOREA, REPUBLIC OF
PI US 2005232938 A1 20051020
AI US 2004-877670 A1 20040625 (10)
PRAI KR 20040419
DT Utility
FS APPLICATION
LREP JORDAN AND HAMBURG LLP, 122 EAST 42ND STREET, SUITE 4000, NEW YORK, NY, 10168, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 1374
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a novel vaccine against Escherichia coli (E. coli) responsible for **urinary tract infections**. The vaccine is a recombinant chimeric protein which is prepared by linking by genetic recombination a gene encoding an antigenic determinant of uropathogenic E. coli to a CTXA2B gene encoding nontoxic A2 and B subunits of Vibrio cholerae cholera toxin (CTX) or a LTXA2B gene encoding nontoxic A2 and B subunits of E. coli heat-labile enterotoxin, wherein a translation product of the CTXA2B or LTXA2B gene serves as an immunogenic adjuvant stimulating mucosal immune responses, expressing the resulting recombinant gene in E. coli, and isolating and purifying an expressed recombinant fusion protein. The recombinant chimeric protein is useful as an oral vaccine with mild side effects and excellent vaccination efficiency against uropathogenic E. coli. Thus, the chimeric vaccine protein can remarkably reduce recurrence of **urinary tract infections**, prevent occurrence of antibiotic-resistant bacteria, and replace the conventional chemotherapy for **urinary tract infections**. Also, the chimeric vaccine protein has other advantages of being capable of being produced and commercialized in a short period with relatively low costs, and being easily modified by replacing its genetic constituents with other genes to provide various vaccines.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 86 USPATFULL on STN
AN 2005:248575 USPATFULL
TI 70 human secreted proteins
IN Ruben, Steven M., Brookeville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Bednarik, Daniel P., Columbia, MD, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Feng, Ping, Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Duan, D. Roxanne, Bethesda, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 2005215775 A1 20050929
AI US 2004-979111 A1 20041102 (10)
RLI Division of Ser. No. US 2000-621011, filed on 20 Jul 2000, GRANTED, Pat. No. US 6878687 Continuation of Ser. No. US 1998-148545, filed on 4 Sep 1998, GRANTED, Pat. No. US 6590075
PRAI WO 1998-US4482 19980306
US 1997-40162P 19970307 (60)
US 1997-40333P 19970307 (60)
US 1997-38621P 19970307 (60)
US 1997-40161P 19970307 (60)
US 1997-40626P 19970307 (60)
US 1997-40336P 19970307 (60)
US 1997-40163P 19970307 (60)
US 1997-47615P 19970523 (60)
US 1997-47600P 19970523 (60)
US 1997-47597P 19970523 (60)
US 1997-47502P 19970523 (60)
US 1997-47633P 19970523 (60)
US 1997-47583P 19970523 (60)
US 1997-47617P 19970523 (60)
US 1997-47618P 19970523 (60)
US 1997-47503P 19970523 (60)
US 1997-47592P 19970523 (60)
US 1997-47581P 19970523 (60)
US 1997-47584P 19970523 (60)
US 1997-47500P 19970523 (60)
US 1997-47587P 19970523 (60)
US 1997-47492P 19970523 (60)
US 1997-47598P 19970523 (60)
US 1997-47613P 19970523 (60)
US 1997-47582P 19970523 (60)
US 1997-47596P 19970523 (60)
US 1997-47612P 19970523 (60)
US 1997-47632P 19970523 (60)
US 1997-47601P 19970523 (60)
US 1997-43580P 19970411 (60)
US 1997-43568P 19970411 (60)
US 1997-43314P 19970411 (60)
US 1997-43569P 19970411 (60)
US 1997-43311P 19970411 (60)
US 1997-43671P 19970411 (60)
US 1997-43674P 19970411 (60)
US 1997-43669P 19970411 (60)

US 1997-43312P 19970411 (60)
US 1997-43313P 19970411 (60)
US 1997-43672P 19970411 (60)
US 1997-43315P 19970411 (60)
US 1997-48974P 19970606 (60)
US 1997-56886P 19970822 (60)
US 1997-56877P 19970822 (60)
US 1997-56889P 19970822 (60)
US 1997-56893P 19970822 (60)
US 1997-56630P 19970822 (60)
US 1997-56878P 19970822 (60)
US 1997-56662P 19970822 (60)
US 1997-56872P 19970822 (60)
US 1997-56882P 19970822 (60)
US 1997-56637P 19970822 (60)
US 1997-56903P 19970822 (60)
US 1997-56888P 19970822 (60)
US 1997-56879P 19970822 (60)
US 1997-56880P 19970822 (60)
US 1997-56894P 19970822 (60)
US 1997-56911P 19970822 (60)
US 1997-56636P 19970822 (60)
US 1997-56874P 19970822 (60)
US 1997-56910P 19970822 (60)
US 1997-56864P 19970822 (60)
US 1997-56631P 19970822 (60)
US 1997-56845P 19970822 (60)
US 1997-56892P 19970822 (60)
US 1997-47595P 19970523 (60)
US 1997-57761P 19970905 (60)
US 1997-47599P 19970523 (60)
US 1997-47588P 19970523 (60)
US 1997-47585P 19970523 (60)
US 1997-47586P 19970523 (60)
US 1997-47590P 19970523 (60)
US 1997-47594P 19970523 (60)
US 1997-47589P 19970523 (60)
US 1997-47593P 19970523 (60)
US 1997-47614P 19970523 (60)
US 1997-43578P 19970411 (60)
US 1997-43576P 19970411 (60)
US 1997-47501P 19970523 (60)
US 1997-43670P 19970411 (60)
US 1997-56632P 19970822 (60)
US 1997-56664P 19970822 (60)
US 1997-56876P 19970822 (60)
US 1997-56881P 19970822 (60)
US 1997-56909P 19970822 (60)
US 1997-56875P 19970822 (60)
US 1997-56862P 19970822 (60)
US 1997-56887P 19970822 (60)
US 1997-56908P 19970822 (60)
US 1997-48964P 19970606 (60)
US 1997-57650P 19970905 (60)
US 1997-56884P 19970822 (60)

DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14367
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic

methods useful for diagnosing and **treating** disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 86 USPATFULL on STN
AN 2005:236070 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 6946134 B1 20050920
AI US 2001-833111 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Hope A.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 23429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 13 OF 86 USPATFULL on STN
AN 2005:226559 USPATFULL
TI Method of administering FimH protein as a vaccine for **urinary tract infections**
IN Langermann, Solomon, Baltimore, MD, UNITED STATES
Ballou, W. Ripley JR., Silver Springs, MD, UNITED STATES
PA MedImmune, Inc. (U.S. corporation)
PI US 2005196408 A1 20050908
AI US 2005-110609 A1 20050419 (11)
RLI Continuation of Ser. No. US 2002-306897, filed on 27 Nov 2002, ABANDONED
Continuation of Ser. No. US 2000-724397, filed on 28 Nov 2000, ABANDONED
PRAI US 2000-226146P 20000818 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 209
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 2733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of stimulating an immune response in a primate utilizing compositions comprising bacterial adhesin proteins and/or immunogenic fragments thereof. The compositions are useful for the prevention and **treatment** of bacterial induced diseases involving bacterial adherence to a target cell, such as diseases of the urinary tract. More specifically, the invention relates to the vaccination of primates, preferably humans, with protein complexes, such as a purified FimH polypeptides, a purified FimC-FimH (FimCH) polypeptide complex, or immunogenic fragments thereof, to

stimulate protective immunity in the recipient against infection by pathogenic bacteria, including all types of Enterobacteriaceae, preferably E. Coli to produce specific immunoglobin molecules in the serum and urine or mucosal secretions of the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 86 USPATFULL on STN
AN 2005:214989 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
Ballance, David J., Berwyn, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES
PI US 2005186664 A1 20050825
AI US 2004-775204 A1 20040211 (10)
RLI Continuation of Ser. No. WO 2002-US40891, filed on 23 Dec 2002, PENDING
PRAI US 2001-341811P 20011221 (60)
US 2002-350358P 20020124 (60)
US 2002-351360P 20020128 (60)
US 2002-359370P 20020226 (60)
US 2002-360000P 20020228 (60)
US 2002-367500P 20020327 (60)
US 2002-370227P 20020408 (60)
US 2002-378950P 20020510 (60)
US 2002-382617P 20020524 (60)
US 2002-383123P 20020528 (60)
US 2002-385708P 20020605 (60)
US 2002-394625P 20020710 (60)
US 2002-398008P 20020724 (60)
US 2002-402131P 20020809 (60)
US 2002-402708P 20020813 (60)
US 2002-411355P 20020918 (60)
US 2002-411426P 20020918 (60)
US 2002-414984P 20021002 (60)
US 2002-417611P 20021011 (60)
US 2002-420246P 20021023 (60)
US 2002-423623P 20021105 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US
CLMN Number of Claims: 21
ECL Exemplary Claim: 1
DRWN 23 Drawing Page(s)
LN.CNT 25129
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 86 USPATFULL on STN
AN 2005:151328 USPATFULL
TI Carbohydrate encapsulated nanoparticles
IN Lin, Chun-Cheng, Fung-Yuan City, TAIWAN, PROVINCE OF CHINA
Chen, Chia-Chu, Taipei, TAIWAN, PROVINCE OF CHINA
Wu, Yi-Chun, Taipei, TAIWAN, PROVINCE OF CHINA
PA Academia Sinica, Taipei, TAIWAN, PROVINCE OF CHINA (non-U.S. corporation)
National Taiwan University, Taipei, TAIWAN, PROVINCE OF CHINA (non-U.S.

corporation)
National Taiwan Normal University, Taipei, TAIWAN, PROVINCE OF CHINA (non-U.S. corporation)
PI US 2005130240 A1 20050616
AI US 2004-782076 A1 20040219 (10)
PRAI US 2003-448716P 20030219 (60)
DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 2061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides carbohydrate encapsulated nanoparticles. In particular, the present invention provides metallic nanoparticles (e.g. gold nanoparticles) that are encapsulated in biologically important carbohydrate molecules, such as sugars, sugar derivatives, P-blood group antigens and analogues thereof. The present invention also provides methods of employing these carbohydrate encapsulated nanoparticles in diagnostic and therapeutic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 86 USPATFULL on STN
AN 2005:137948 USPATFULL
TI Enzymes
IN Chawla, Narinder K., Union City, CA, UNITED STATES
Lee, Soo Yuen, Daly City, CA, UNITED STATES
Ring, Huijun Z., Los Altos, CA, UNITED STATES
Lee, Ernestine A., Castro Valley, CA, UNITED STATES
Forsythe, Ian J., Redwood City, CA, UNITED STATES
Khare, Reena, Saratoga, CA, UNITED STATES
Tran, Uyen K., San Jose, CA, UNITED STATES
Kable, Amy E., San Francisco, CA, UNITED STATES
Richardson, Thomas W., Redwood City, CA, UNITED STATES
Emerling, Brooke M., Palo Alto, CA, UNITED STATES
Lindquist, Erika A., Alameda, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Hafalia, April J.A., Santa Clara, CA, UNITED STATES
Jin, Pei, Palo Alto, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Li, Joana X., San Francisco, CA, UNITED STATES
Marquis, Joseph P., San Jose, CA, UNITED STATES
Gorvad, Ann E., Livermore, CA, UNITED STATES
Sprague, William W., Sacramento, CA, UNITED STATES
Becha, Shanya D., Castro Valley, CA, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
PI US 2005118594 A1 20050602
AI US 2003-498788 A1 20021212 (10)
WO 2002-US40161 20021212
PRAI US 2003-340357P 20011214 (60)
US 2003-342962P 20011220 (60)
US 2003-343558P 20011221 (60)
US 2003-351107P 20020122 (60)
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007, US
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 16691
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Various embodiments of the invention provide human enzymes (ENZM) and polynucleotides which identify and encode-ENZM. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for

diagnosing, **treating**, or preventing disorders associated with aberrant expression of ENZM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 86 USPATFULL on STN
AN 2005:117724 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2005100991 A1 20050512
AI US 2004-932104 A1 20040902 (10)
RLI Division of Ser. No. US 2001-833118, filed on 12 Apr 2001, PENDING
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 15444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 86 USPATFULL on STN
AN 2005:89368 USPATFULL
TI Protein HMAAD57
IN Ruben, Steven M., Brookeville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Komatsoulis, George, Silver Spring, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 6878687 B1 20050412
AI US 2000-621011 20000720 (9)
RLI Continuation of Ser. No. US 1998-148545, filed on 4 Sep 1998, Pat. No. US 6590075 Continuation-in-part of Ser. No. WO 1998-US4482, filed on 6 Mar 1998, PENDING
PRAI US 1997-57761P 19970905 (60)
US 1997-57650P 19970905 (60)
US 1997-56886P 19970822 (60)
US 1997-56877P 19970822 (60)
US 1997-56889P 19970822 (60)
US 1997-56893P 19970822 (60)
US 1997-56630P 19970822 (60)
US 1997-56878P 19970822 (60)
US 1997-56662P 19970822 (60)
US 1997-56872P 19970822 (60)
US 1997-56882P 19970822 (60)
US 1997-56637P 19970822 (60)
US 1997-56903P 19970822 (60)
US 1997-56888P 19970822 (60)
US 1997-56879P 19970822 (60)
US 1997-56880P 19970822 (60)
US 1997-56894P 19970822 (60)
US 1997-56911P 19970822 (60)
US 1997-56636P 19970822 (60)

US 1997-56874P 19970822 (60)
US 1997-56910P 19970822 (60)
US 1997-56864P 19970822 (60)
US 1997-56631P 19970822 (60)
US 1997-56845P 19970822 (60)
US 1997-56892P 19970822 (60)
US 1997-56632P 19970822 (60)
US 1997-56664P 19970822 (60)
US 1997-56876P 19970822 (60)
US 1997-56881P 19970822 (60)
US 1997-56909P 19970822 (60)
US 1997-56875P 19970822 (60)
US 1997-56862P 19970822 (60)
US 1997-56887P 19970822 (60)
US 1997-56908P 19970822 (60)
US 1997-56884P 19970822 (60)
US 1997-48974P 19970606 (60)
US 1997-48964P 19970606 (60)
US 1997-47615P 19970523 (60)
US 1997-47600P 19970523 (60)
US 1997-47597P 19970523 (60)
US 1997-47502P 19970523 (60)
US 1997-47633P 19970523 (60)
US 1997-47583P 19970523 (60)
US 1997-47617P 19970523 (60)
US 1997-47618P 19970523 (60)
US 1997-47583P 19970523 (60)
US 1997-47592P 19970523 (60)
US 1997-47581P 19970523 (60)
US 1997-47584P 19970523 (60)
US 1997-47500P 19970523 (60)
US 1997-47587P 19970523 (60)
US 1997-47492P 19970523 (60)
US 1997-47598P 19970523 (60)
US 1997-47613P 19970523 (60)
US 1997-47582P 19970523 (60)
US 1997-47596P 19970523 (60)
US 1997-47612P 19970523 (60)
US 1997-47632P 19970523 (60)
US 1997-47601P 19970523 (60)
US 1997-47595P 19970523 (60)
US 1997-47599P 19970523 (60)
US 1997-47588P 19970523 (60)
US 1997-47585P 19970523 (60)
US 1997-47586P 19970523 (60)
US 1997-47590P 19970523 (60)
US 1997-47594P 19970523 (60)
US 1997-47589P 19970523 (60)
US 1997-47593P 19970523 (60)
US 1997-47614P 19970523 (60)
US 1997-47501P 19970523 (60)
US 1997-43580P 19970411 (60)
US 1997-43568P 19970411 (60)
US 1997-43314P 19970411 (60)
US 1997-43569P 19970411 (60)
US 1997-43311P 19970411 (60)
US 1997-43671P 19970411 (60)
US 1997-43674P 19970411 (60)
US 1997-43669P 19970411 (60)
US 1997-43312P 19970411 (60)
US 1997-43313P 19970411 (60)
US 1997-43672P 19970411 (60)
US 1997-43315P 19970411 (60)
US 1997-43578P 19970411 (60)
US 1997-43576P 19970411 (60)
US 1997-43670P 19970411 (60)
US 1997-40162P 19970307 (60)
US 1997-40333P 19970307 (60)
US 1997-38621P 19970307 (60)

PI US 1997-40161P 19970307 (60)
US 1997-40626P 19970307 (60)
US 1997-40334P 19970307 (60)
US 1997-40336P 19970307 (60)
US 1997-40163P 19970307 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon P.; Assistant Examiner: Kam, Chih-Min
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 13992
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and **treating** disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 86 USPATFULL on STN
AN 2005:77535 USPATFULL
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, United States
Kuehn, Meta, Berkeley, CA, United States
Xu, Zheng, Blue Bell, PA, United States
Ogg, Derek, Uppsala, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, United States
Kihlberg, Jan, Dalby, SWEDEN
PA SIGA Pharmaceuticals, Inc., New York, NY, United States (U.S. corporation)
Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 6872542 B1 20050329
AI US 2001-799584 20010307 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996 Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 5301
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 86 USPATFULL on STN
AN 2005:63530 USPATFULL
TI Albumin fusion proteins

IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2005054570 A1 20050310
AI US 2004-775180 A1 20040211 (10)
RLI Continuation of Ser. No. WO 2002-US40892, filed on 23 Dec 2002, PENDING
PRAI US 2001-341811P 20011221 (60)
US 2002-360000P 20020228 (60)
US 2002-378950P 20020510 (60)
US 2002-398008P 20020724 (60)
US 2002-411355P 20020918 (60)
US 2002-414984P 20021002 (60)
US 2002-417611P 20021011 (60)
US 2002-420246P 20021023 (60)
US 2002-423623P 20021105 (60)
US 2002-350358P 20020124 (60)
US 2002-359370P 20020226 (60)
US 2002-367500P 20020327 (60)
US 2002-402131P 20020809 (60)
US 2002-402708P 20020813 (60)
US 2002-370227P 20020408 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 20949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating** or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 21 OF 86 USPATFULL on STN
AN 2005:63014 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2005054051 A1 20050310
AI US 2004-922142 A1 20040820 (10)
RLI Division of Ser. No. US 2001-832929, filed on 12 Apr 2001, PENDING
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 17526
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion

proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 22 OF 86 USPATFULL on STN
AN 2005:57259 USPATFULL
TI EphA2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
IN Kiener, Peter A., Doylestown, PA, UNITED STATES
Kinch, Michael S., Laytonsville, MD, UNITED STATES
Langermann, Solomon, Baltimore, MD, UNITED STATES
PI US 2005049176 A1 20050303
AI US 2004-823259 A1 20040412 (10)
PRAI US 2003-462009P 20030411 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3294
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions designed for the **treatment**, management, or prevention of a hypoproliferative cell disorder, especially those disorders relating to the destruction, shedding, or inadequate proliferation of epithelial and/or endothelial cells, particularly interstitial cystitis (IC) and lesions associated with inflammatory bowel disease (IBD). The methods of the invention comprise the administration of an effective amount of one or more agents that are antagonists of EphA2. In certain embodiments, the EphA2 antagonistic agent of the invention decreases EphA2-endogenous ligand binding, upregulates EphA2 gene expression and/or translation, increases EphA2 protein stability or protein accumulation, decreases EphA2 cytoplasmic tail phosphorylation, promotes EphA2 kinase activity (other than autophosphorylation or ligand-mediated EphA2 signaling), increases proliferation of EphA2 expressing cells, increases survival of EphA2 expressing cells, and/or maintains/reconstitutes epithelial and/or endothelial cell layer integrity. The invention also provides pharmaceutical compositions comprising one or more EphA2 antagonistic agents of the invention either alone or in combination with one or more other agents useful for therapy for a hypoproliferative cell disorder. Diagnostic methods and methods for screening for therapeutically useful agents are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 23 OF 86 USPATFULL on STN
AN 2005:43296 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2005037022 A1 20050217
AI US 2004-816042 A1 20040402 (10)
RLI Continuation of Ser. No. WO 2002-US31794, filed on 4 Oct 2002, PENDING
PRAI US 2001-327281P 20011005 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 17090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using

these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 24 OF 86 USPATFULL on STN
AN 2005:30345 USPATFULL
TI Capsular polysaccharide adhesin antigen, preparation, purification and use
IN Pier, Gerald B., Brookline, MA, UNITED STATES
PA The Brigham And Women's Hospital, Inc., Boston, MA, 02115 (U.S. corporation)
PI US 2005025775 A1 20050203
AI US 2004-856123 A1 20040528 (10)
RLI Continuation of Ser. No. US 2002-93582, filed on 8 Mar 2002, GRANTED, Pat. No. US 6743431 Division of Ser. No. US 1999-393832, filed on 10 Sep 1999, GRANTED, Pat. No. US 6399066 Division of Ser. No. US 1994-336688, filed on 7 Nov 1994, GRANTED, Pat. No. US 5980910 Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, ABANDONED Continuation of Ser. No. US 1991-727982, filed on 10 Jul 1991, ABANDONED Division of Ser. No. US 1988-250417, filed on 28 Sep 1988, GRANTED, Pat. No. US 5055455
DT Utility
FS APPLICATION
LREP Patrick R.H. Waller, WOLF GREENFIELD & SACKS PC, 600 Atlantic Avenue, Boston, MA, 02210-2211
CLMN Number of Claims: 5
ECL Exemplary Claim: CLM-01-30
DRWN 5 Drawing Page(s)
LN.CNT 788
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a gonoral method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymoric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 86 USPATFULL on STN
AN 2005:10558 USPATFULL
TI Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
IN Miller, Fred H., Tampa, FL, UNITED STATES
PI US 2005008690 A1 20050113
AI US 2004-804576 A1 20040319 (10)
RLI Continuation-in-part of Ser. No. WO 2003-US10816, filed on 9 Apr 2003, PENDING
PRAI US 2002-371448P 20020410 (60)
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
CLMN Number of Claims: 118
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 6126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A multi-compartment **capsule**, comprising, a first receiving chamber comprising at least one ingredient having a first physical state, wherein said ingredient is selected from the group consisting of

a nutraceutical, a vitamin, a dietary supplement and a mineral; and a second receiving chamber comprising at least one ingredient having a second physical state, wherein said ingredient is selected from the group consisting of a nutraccutical, a vitamin, a dietary supplement and a mineral; wherein said first physical state of said ingredient of said first receiving chamber being different from said second physical state of said ingredient of said second receiving chamber; and said ingredient of said first receiving chamber being different from said ingredient of said second receiving chamber.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 86 USPATFULL on STN
AN 2005:10484 USPATFULL
TI Recombinant human interferon-beta-1b polypeptides
IN Nestaas, Eirik, San Francisco, CA, UNITED STATES
Pungor, Erno, Millbrae, CA, UNITED STATES
PA Schering Aktiengesellschaft, Berlin, GERMANY, FEDERAL REPUBLIC OF (U.S. corporation)
PI US 2005008616 A1 20050113
AI US 2004-886414 A1 20040706 (10)
PRAI US 2003-486657P 20030711 (60)
DT Utility
FS APPLICATION
LREP BERLEX BIOSCIENCES, PATENT DEPARTMENT, 2600 HILLTOP DRIVE, P.O. BOX 4099, RICHMOND, CA, 94804-0099
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 4 Drawing Page(s)
LN.CNT 1658
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to recombinant human interferon-β-1b ("IFN-β-1b") polypeptides, or fragments, analogs, derivatives, or variants thereof, having an improved specific activity. The present invention also relates to pharmaceutical compositions comprising such IFN-β-1b polypeptides, or fragments, analogs, derivatives, or variants thereof, useful for **treating** multiple sclerosis. The present invention further relates to methods of producing such IFN-β-1b compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 27 OF 86 USPATFULL on STN
AN 2004:306557 USPATFULL
TI Use of potent, selective and non-toxic c-kit inhibitors for **treating** bacterial infections
IN Moussy, Alain, Paris, FRANCE
Kinet, Jean-Pierre, Lexington, MA, UNITED STATES
PI US 2004241226 A1 20041202
AI US 2004-490287 A1 20040322 (10)
WO 2002-IB4251 20020920
PRAI US 2001-323313P 20010920 (60)
DT Utility
FS APPLICATION
LREP SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for **treating** bacterial infections, preferably infections caused by FimH expressing bacteria, comprising administering a tyrosine kinase inhibitor to a human in need of such **treatment**, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote detah of IL-3 dependent cells cultured to presence of IL-3.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 28 OF 86 USPATFULL on STN
AN 2004:286238 USPATFULL
TI Novel multifunctional adhesin proteins and their display in microbial cells
IN Schembri, Mark Andrew, Skovlunde, DENMARK
Klemm, Per, Naerum, DENMARK
PA GYRE LTD., London, UNITED KINGDOM, SE1 6LN (non-U.S. corporation)
PI US 2004224400 A1 20041111
AI US 2003-681381 A1 20031009 (10)
RLI Continuation of Ser. No. US 1999-301704, filed on 29 Apr 1999, ABANDONED
PRAI DK 1998-598 19980430
US 1998-83794P 19980501 (60)
DT Utility
FS APPLICATION
LREP HUNTON & WILLIAMS LLP, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 1557
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Recombinant cells expressing a multifunctional adhesin protein derived from a naturally occurring adhesin, containing a binding domain that is capable of binding to an organic receptor and a binding domain that is capable of binding to a compound to which the naturally occurring adhesin protein substantially does not bind. The cells or modified adhesin proteins, optionally in immobilized form, are useful for separating organic and inorganic compounds including toxic or precious metals from an environment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 29 OF 86 USPATFULL on STN
AN 2004:233765 USPATFULL
TI **D-mannose** contraceptives
IN Benedict, Dale L., Fayetteville, AR, UNITED STATES
Benedict, Martha J., Fayetteville, AR, UNITED STATES
PI US 2004180839 A1 20040916
AI US 2004-810522 A1 20040326 (10)
RLI Continuation of Ser. No. US 2002-231399, filed on 29 Aug 2002, GRANTED, Pat. No. US 6753319
DT Utility
FS APPLICATION
LREP Steven Thrasher, 391 Sandhill Dr., Richardson, TX, 75080
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 159
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns the use of **D-mannose** to prevent or inhibit uniting of sperm and egg in the conception process. The administration of **D-Mannose** to a female such that the environment of an egg has sufficient **D-Mannose** to inhibit interaction of sperm and the egg and prevent or inhibit conception. **D-Mannose** dosages may be complimentary to other methods of birth control to enhance their effectiveness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 30 OF 86 USPATFULL on STN
AN 2004:221354 USPATFULL
TI ALBUMIN FUSION PROTEINS
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2004171123 A1 20040902
US 6926898 B2 20050809

AI US 2001-832929 A1 20010412 (9)
DT Utility
FS APPLICATION
LREP FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 17424
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 31 OF 86 USPATFULL on STN
AN 2004:203036 USPATFULL
TI Plant proanthocyanidin extract effective at inhibiting utility
IN Howell, Amy B., Hamilton, NJ, UNITED STATES
Vorsa, Nicholi, Atco, NJ, UNITED STATES
PA Rutgers, The State University of New Jersey, New Brunswick, NJ (U.S. corporation)
PI US 2004156925 A1 20040812
AI US 2004-772566 A1 20040204 (10)
RLI Division of Ser. No. US 2003-428063, filed on 30 Apr 2003, GRANTED, Pat. No. US 6720353 Division of Ser. No. US 1998-145694, filed on 2 Sep 1998, GRANTED, Pat. No. US 6608102
PRAI US 1997-58307P 19970909 (60)
DT Utility
FS APPLICATION
LREP WILMER CUTLER PICKERING HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY, 10022
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 1770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and **treatment** of **urinary tract infections** caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 32 OF 86 USPATFULL on STN
AN 2004:196404 USPATFULL
TI Strain of micro-organism lactobacillus fermentum me-3 as novel anti-microbial and anti-oxidative probiotic
IN Mikelsaar, Marika, Tartu, ESTONIA
Zilmer, Mikhel, Tartu, ESTONIA

Kullisaaar, Tiiu, Tartu, ESTONIA
Annuk, Heidi, Tartu, ESTONIA
Songisepp, Epp, Polva, ESTONIA
PI US 2004151708 A1 20040805
AI US 2003-481713 A1 20031222 (10)
WO 2002-EE6 20020621
PRAI EE 2001-200100356 20010629
DT Utility
FS APPLICATION
LREP James G Dilmore, Reed Smith, P O Box 488, Pittsburgh, PA, 15230-0488
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The strain of micro-organism Lactobacillus fermentum ME-3 is a novel anti-microbial and anti-oxidative probiotic. It has a high anti-microbial effect on Escherichia coli, Shigella sonnei, Staphylococcus aureus, Salmonella typhimurium, and moderate activity against Helicobacter pylori strains. The strain of micro-organism possesses Mn-superoxide dismutase and both its lysates and intact cells have high anti-oxidative activity, increasing the glutathione red-ox ratio in blood sera and able to capture toxic hydroxyl radicals. The strain of micro-organism could be used as a probiotic for the production of functional food (yoghurt, cheese) and non-comestibles (tablets, **capsules**) for the prophylaxis of intestinal and uroinfections, both for the prevention and **treatment** of chronic diseases, caused by prolonged oxidative stress.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 33 OF 86 USPATFULL on STN
AN 2004:190686 USPATFULL
TI Method and composition for maintaining urinary tract health in the face of infections
IN Oneal, Joseph, Irving, TX, UNITED STATES
White, Gary, Irving, TX, UNITED STATES
PI US 2004147459 A1 20040729
AI US 2003-691423 A1 20031022 (10)
PRAI US 2002-420696P 20021023 (60)
DT Utility
FS APPLICATION
LREP CARSTENS YEE & CAHOON, LLP, P O BOX 802334, DALLAS, TX, 75380
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The sugar mannose has been used to maintain urinary tract health in the face of E. coli infections. An optimal dose is disclosed to be of one teaspoon (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophalaxis is one-half teaspoon (1 gram) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one teaspoon is taken an hour prior to intimate relations and an additional one teaspoon immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala, white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 34 OF 86 USPATFULL on STN
AN 2004:172003 USPATFULL
TI Methods and compositions for inhibiting adhesion by microorganisms
IN Doyle, Ron J., Louisville, KY, UNITED STATES
Cowan, M. M., Cincinnati, OH, UNITED STATES
PI US 2004132164 A1 20040708
AI US 2003-741740 A1 20031218 (10)
RLI Continuation of Ser. No. US 2000-750857, filed on 29 Dec 2000, ABANDONED

PRAI US 1999-173821P 19991230 (60)
DT Utility
FS APPLICATION
LREP Genencor International, Inc., 925 Page Mill Road, Palo Alto, CA, 94034-1013
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2653
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed generally to compositions and methods for enzymatic reduction of adhesion by a microorganism to cells, tissues, extracellular matrix, teeth, and/or dental prostheses. The compositions of the invention include pharmaceutical compositions and oral care compositions containing an enzyme that can reduce binding of a microbe to a cell, a tissue, or a surface. Suitable enzymes include a polyphenol oxidase and an asparaginase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 35 OF 86 USPATFULL on STN
AN 2004:82309 USPATFULL
TI Combination of probiotics
IN Mayra-Makinen, Annika, Helsinki, FINLAND
Suomalainen, Tarja, Helsinki, FINLAND
Vaarala, Outi, Helsinki, FINLAND
PI US 2004062758 A1 20040401
AI US 2003-470151 A1 20031022 (10)
WO 2002-FI35 20020117
PRAI FI 2001-157 20010125
DT Utility
FS APPLICATION
LREP Nixon & Vanderhye, 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 827
AB The invention relates to a probiotic combination comprising different combinations of lactobacilli. propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.

L6 ANSWER 36 OF 86 USPATFULL on STN
AN 2004:13611 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2004010134 A1 20040115
AI US 2001-833245 A1 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 25066
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and

methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 86 USPATFULL on STN
AN 2003:318724 USPATFULL
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, UNITED STATES
Kuehn, Meta, Berkeley, CA, UNITED STATES
Xu, Zheng, Blue Bell, PA, UNITED STATES
Ogg, Derek, Uppsala, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, UNITED STATES
Kihlberg, Jan, Dalby, SWEDEN
PI US 2003224468 A1 20031204
AI US 2001-799680 A1 20010307 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, GRANTED, Pat. No. US 6420127 Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED
DT Utility
FS APPLICATION
LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 5629
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 38 OF 86 USPATFULL on STN
AN 2003:312278 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2003219875 A1 20031127
US 6905688 B2 20050614
AI US 2001-833118 A1 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid

molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 86 USPATFULL on STN
AN 2003:289203 USPATFULL
TI Plant proanthocyanidin extract effective at inhibiting
IN Howell, Amy B., Hammonton, NJ, UNITED STATES
Vorsa, Nicholi, Atco, NJ, UNITED STATES
PA Rutgers, The State University of New Jersey, New Brunswick, NJ, UNITED STATES (U.S. corporation)
PI US 2003203962 A1 20031030
US 6720353 B2 20040413
AI US 2003-428063 A1 20030430 (10)
RLI Division of Ser. No. US 1998-145694, filed on 2 Sep 1998, GRANTED, Pat. No. US 6608102
PRAI US 1997-58307P 19970909 (60)
DT Utility
FS APPLICATION
LREP HALE AND DORR LLP, 300 PARK AVENUE, NEW YORK, NY, 10022
CLMN Number of Claims: 90
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 1768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and **treatment** of **urinary tract infections** caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 40 OF 86 USPATFULL on STN
AN 2003:282728 USPATFULL
TI Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
IN Langermann, Solomon, Baltimore, MD, UNITED STATES
Hultgren, Scott J., Town and Country, MO, UNITED STATES
Hung, Chia-Suei, St. Louis, MO, UNITED STATES
Bouckaert, Julie, St. Louis, MO, UNITED STATES
PI US 2003199071 A1 20031023
AI US 2001-15085 A1 20011210 (10)
PRAI US 2000-254353P 20001208 (60)
US 2001-301878P 20010629 (60)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 47 Drawing Page(s)

LN.CNT 6520
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species, especially human patients, with variants of the E. coli FimCH protein that elicit antibodies that have better functional inhibitory activity than antibodies raised against wild type protein. In particular, such variants include mutations that promote a more open confirmation of the FimH protein, particularly in regions involved in mannose binding, to expose regions previously poorly exposed and mutations that abolish a significantly reduce mannose binding. In another aspect, the invention provides antibodies against such proteins and protein complexes that may be used in passive immunization to protect or **treat** pathogenic bacterial infections. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of FimCH bound to mannose, and subsets thereof, and methods of using the crystal structure to provide candidate amino acid residues for mutation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 86 USPATFULL on STN
AN 2003:282700 USPATFULL
TI Albumin fusion proteins
IN Ballance, David J., Berwyn, PA, UNITED STATES
Sleep, Darrell, West Bridgford, UNITED KINGDOM
Prior, Christopher P., Rosemont, PA, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES
PI US 2003199043 A1 20031023
AI US 2001-832501 A1 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 18 Drawing Page(s)
LN.CNT 14339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 86 USPATFULL on STN
AN 2003:282649 USPATFULL
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, UNITED STATES
Kuehn, Meta, Berkeley, CA, UNITED STATES
Xu, Zheng, Blue Bell, PA, UNITED STATES
Ogg, Derek, Stockholm, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, UNITED STATES
Kihlberg, Jan, Dalby, SWEDEN
PI US 2003198992 A1 20031023

AI US 2001-798932 A1 20010306 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, GRANTED, Pat. No. US 6420127 Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, PENDING Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED
DT Utility
FS APPLICATION
LREP BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN 24 Drawing Page(s)
LN.CNT 5605
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 43 OF 86 USPATFULL on STN
AN 2003:244853 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Sadeghi, Homayoun, Doylestown, PA, UNITED STATES
Prior, Christopher P., Rosemont, PA, UNITED STATES
Turner, Andrew J., Eagleville, PA, UNITED STATES
PI US 2003171267 A1 20030911
AI US 2001-833117 A1 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 13208
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 44 OF 86 USPATFULL on STN
AN 2003:222129 USPATFULL
TI Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with P-type fimbriae to surfaces
IN Howell, Amy B., Hammonton, NJ, United States
Vorsa, Nicholi, Atco, NJ, United States
PA Rutgers, the State University of New Jersey, New Brunswick, NJ, United States (U.S. corporation)
PI US 6608102 B1 20030819

AI US 1998-145694 19980902 (9)
PRAI US 1997-58307P 19970909 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Solola, Taofiq
LREP Hale and Dorr LLP
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1377
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and **treatment** of **urinary tract infections** caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 45 OF 86 USPATFULL on STN
AN 2003:206834 USPATFULL
TI Chemokine beta-1 fusion proteins
IN Bell, Adam, Germantown, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2003143191 A1 20030731
AI US 2002-153604 A1 20020524 (10)
PRAI US 2001-293212P 20010525 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 21 Drawing Page(s)
LN.CNT 15446
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ckβ-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-γ, and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of **treating**, preventing, ameliorating diseases using such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 46 OF 86 USPATFULL on STN
AN 2003:200465 USPATFULL
TI Method of administering FimH protein as a vaccine for **urinary tract infections**
IN Langermann, Solomon, Baltimore, MD, UNITED STATES
Ballou, W. Ripley, JR., Silver Springs, MD, UNITED STATES
PA MedImmune, Inc. (U.S. corporation)
PI US 2003138449 A1 20030724
AI US 2002-306897 A1 20021127 (10)
RLI Continuation of Ser. No. US 2000-724397, filed on 28 Nov 2000, ABANDONED
PRAI US 2000-226146P 20000818 (60)
DT Utility

FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 209
ECL Exemplary Claim: 1
DRWN 9 Drawing Page(s)
LN.CNT 3107
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods of stimulating an immune response in a primate utilizing compositions comprising bacterial adhesin proteins and/or immunogenic fragments thereof. The compositions are useful for the prevention and **treatment** of bacterial induced diseases involving bacterial adherence to a target cell, such as diseases of the urinary tract. More specifically, the invention relates to the vaccination of primates, preferably humans, with protein complexes, such as a purified FimH polypeptides, a purified FimC-FimH (FimCH) polypeptide complex, or immunogenic fragments thereof, to stimulate protective immunity in the recipient against infection by pathogenic bacteria, including all types of Enterobacteriaceae, preferably E. coli to produce specific immunoglobin molecules in the serum and urine or mucosal secretions of the subject.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 47 OF 86 USPATFULL on STN
AN 2003:181414 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2003125247 A1 20030703
AI US 2001-833041 A1 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 20 Drawing Page(s)
LN.CNT 15235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 48 OF 86 USPATFULL on STN
AN 2003:180804 USPATFULL
TI Novel proteins involved in the synthesis and assembly of O-antigen in pseudomonas aeruginosa
IN Lam, Joseph S., Guelph, CANADA
Burrows, Lori L., Guelph, CANADA
Charter, Deborah, Guelph, CANADA
Kievit, Teresa de, Guelph, CANADA
PA University of Guelph (non-U.S. corporation)
PI US 2003124634 A1 20030703
AI US 2002-216209 A1 20020812 (10)
RLI Continuation of Ser. No. US 1999-352994, filed on 13 Jul 1999, ABANDONED
Division of Ser. No. US 1997-846762, filed on 30 Apr 1997, GRANTED, Pat. No. US 5994072
PRAI US 1996-16510P 19960430 (60)

US 1997-39473P 19970227 (60)
DT Utility
FS APPLICATION
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 63 Drawing Page(s)
LN.CNT 6959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel nucleic acid molecules encoding proteins involved in the synthesis and assembly of O-antigen in P. aeruginosa; and novel proteins encoded by the nucleic acid molecules are described. Methods are disclosed for detecting P.aeruginosa in a sample by determining the presence of the proteins or a nucleic acid molecule encoding the proteins in the sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 49 OF 86 USPATFULL on STN
AN 2003:106731 USPATFULL
TI **D-Mannose** contraceptives
IN Benedict, Dale L., Feyettsville, AR, UNITED STATES
PI US 2003073643 A1 20030417
US 6753319 B2 20040622
AI US 2002-231399 A1 20020829 (10)
PRAI US 2001-315661P 20010829 (60)
DT Utility
FS APPLICATION
LREP Daniel S. Hodgins, Jackson Walker L.L.P., 112 E. Pecan, Ste. 2100, San Antonio, TX, 78205
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 161
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns the use of **D-Mannose** to prevent or inhibit uniting of sperm and egg in the conception process. The administration of **D-Mannose** to a female such that the environment of an egg has sufficient **D-Mannose** to inhibit interaction of sperm and the egg and prevent or inhibit conception. **D-Mannose** dosages may be complimentary to other methods of birth control to enhance their effectiveness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 50 OF 86 USPATFULL on STN
AN 2003:65335 USPATFULL
TI 67 Human secreted proteins
IN Ruben, Steven M., Olney, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Endress, Gregory A., Potomac, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
PI US 2003045459 A1 20030306
AI US 2001-813153 A1 20010321 (9)
RLI Continuation of Ser. No. US 1999-363044, filed on 29 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999, UNKNOWN
PRAI US 1998-73160P 19980130 (60)
US 1998-73159P 19980130 (60)
US 1998-73165P 19980130 (60)

US 1998-73164P 19980130 (60)
US 1998-73167P 19980130 (60)
US 1998-73162P 19980130 (60)
US 1998-73161P 19980130 (60)
US 1998-73170P 19980130 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 14136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 36 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and **treating** disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 51 OF 86 USPATFULL on STN
AN 2003:37487 USPATFULL
TI Secreted Protein HODAZ50
IN RUBEN, STEVEN M., OLNEY, MD, UNITED STATES
ROSEN, CRAIG A., LAYTONSVILLE, MD, UNITED STATES
FISCHER, CARRIE L., BURKE, VA, UNITED STATES
SOPPET, DANIEL R., CENTREVILLE, MD, UNITED STATES
CARTER, KENNETH C., POTOMAC, MD, UNITED STATES
BEDNARIK, DANIEL R., COLUMBIA, MD, UNITED STATES
ENDRESS, GREGORY A., POTOMAC, MD, UNITED STATES
YU, GUO-LIANG, SAN MATEO, CA, UNITED STATES
NI, JIAN, ROCKVILLE, MD, UNITED STATES
FENG, PING, GAITHERSBURG, MD, UNITED STATES
YOUNG, PAUL E., GAITHERSBURG, MD, UNITED STATES
GREENE, JOHN M., GAITHERSBURG, MD, UNITED STATES
FERRIE, ANN M., TEWKSBURY, MA, UNITED STATES
DUAN, ROXANNE, BETHESDA, MD, UNITED STATES
HU, JING-SHAN, SUNNYVALE, CA, UNITED STATES
FLORENCE, KIMBERLY A., ROCKVILLE, MD, UNITED STATES
OLSEN, HENRIK S., GAITHERSBURG, MD, UNITED STATES
EBNER, REINHARD, GAITHERSBURG, MD, UNITED STATES
BREWER, LAURIE A., ST. PAUL, MN, UNITED STATES
SHI, YANGGU, GAITHERSBURG, MD, UNITED STATES
PI US 2003027132 A1 20030206
US 6590075 B2 20030708
AI US 1998-148545 A1 19980904 (9)
RLI Continuation-in-part of Ser. No. WO 1998-US4482, filed on 6 Mar 1998, PENDING
PRAI US 1997-40162P 19970307 (60)
US 1997-40333P 19970307 (60)
US 1997-38621P 19970307 (60)
US 1997-40161P 19970307 (60)
US 1997-40626P 19970307 (60)
US 1997-40334P 19970307 (60)
US 1997-40336P 19970307 (60)
US 1997-40163P 19970307 (60)
US 1997-47600P 19970523 (60)
US 1997-47615P 19970523 (60)
US 1997-47597P 19970523 (60)
US 1997-47502P 19970523 (60)
US 1997-47633P 19970523 (60)
US 1997-47583P 19970523 (60)
US 1997-47617P 19970523 (60)
US 1997-47618P 19970523 (60)
US 1997-40162P 19970307 (60)
US 1997-40333P 19970307 (60)

US 1997-38621P 19970307 (60)
US 1997-40161P 19970307 (60)
US 1997-40626P 19970307 (60)
US 1997-40334P 19970307 (60)
US 1997-40336P 19970307 (60)
US 1997-40163P 19970307 (60)
US 1997-47615P 19970523 (60)
US 1997-47600P 19970523 (60)
US 1997-47597P 19970523 (60)
US 1997-47502P 19970523 (60)
US 1997-47633P 19970523 (60)
US 1997-47583P 19970523 (60)
US 1997-47617P 19970523 (60)
US 1997-47618P 19970523 (60)
US 1997-47503P 19970523 (60)
US 1997-47592P 19970523 (60)
US 1997-47581P 19970523 (60)
US 1997-47584P 19970523 (60)
US 1997-47500P 19970523 (60)
US 1997-47587P 19970523 (60)
US 1997-47492P 19970523 (60)
US 1997-47598P 19970523 (60)
US 1997-47613P 19970523 (60)
US 1997-47582P 19970523 (60)
US 1997-47596P 19970523 (60)
US 1997-47612P 19970523 (60)
US 1997-47632P 19970523 (60)
US 1997-47601P 19970523 (60)
US 1997-43580P 19970411 (60)
US 1997-43568P 19970411 (60)
US 1997-43314P 19970411 (60)
US 1997-43569P 19970411 (60)
US 1997-43311P 19970411 (60)
US 1997-43671P 19970411 (60)
US 1997-43674P 19970411 (60)
US 1997-43669P 19970411 (60)
US 1997-43312P 19970411 (60)
US 1997-43313P 19970411 (60)
US 1997-43672P 19970411 (60)
US 1997-43315P 19970411 (60)
US 1997-48974P 19970606 (60)
US 1997-56886P 19970822 (60)
US 1997-56877P 19970822 (60)
US 1997-56889P 19970822 (60)
US 1997-56893P 19970822 (60)
US 1997-56630P 19970822 (60)
US 1997-56878P 19970822 (60)
US 1997-56662P 19970822 (60)
US 1997-56872P 19970822 (60)
US 1997-56882P 19970822 (60)
US 1997-56637P 19970822 (60)
US 1997-56903P 19970822 (60)
US 1997-56888P 19970822 (60)
US 1997-56879P 19970822 (60)
US 1997-56880P 19970822 (60)
US 1997-56894P 19970822 (60)
US 1997-56911P 19970822 (60)
US 1997-56636P 19970822 (60)
US 1997-56874P 19970822 (60)
US 1997-56910P 19970822 (60)
US 1997-56864P 19970822 (60)
US 1997-56631P 19970822 (60)
US 1997-56845P 19970822 (60)
US 1997-56892P 19970822 (60)
US 1997-47595P 19970523 (60)
US 1997-57761P 19970905 (60)
US 1997-47599P 19970523 (60)
US 1997-47588P 19970523 (60)
US 1997-47585P 19970523 (60)

US 1997-47586P 19970523 (60)
US 1997-47590P 19970523 (60)
US 1997-47594P 19970523 (60)
US 1997-47589P 19970523 (60)
US 1997-47593P 19970523 (60)
US 1997-47614P 19970523 (60)
US 1997-43578P 19970411 (60)
US 1997-43576P 19970411 (60)
US 1997-47501P 19970523 (60)
US 1997-43670P 19970411 (60)
US 1997-56632P 19970822 (60)
US 1997-56664P 19970822 (60)
US 1997-56876P 19970822 (60)
US 1997-56881P 19970822 (60)
US 1997-56909P 19970822 (60)
US 1997-56875P 19970822 (60)
US 1997-56862P 19970822 (60)
US 1997-56887P 19970822 (60)
US 1997-56908P 19970822 (60)
US 1997-48964P 19970606 (60)
US 1997-57650P 19970905 (60)
US 1997-56884P 19970822 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and **treating** disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 52 OF 86 USPATFULL on STN
AN 2002:294626 USPATFULL
TI Secreted protein HRGDF73
IN Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Bednarik, Daniel P., Columbia, MD, UNITED STATES
Endress, Gregory A., Potomac, MD, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
Duan, Roxanne, Bethesda, MD, UNITED STATES
Hu, Jing-Shan, Sunnyvale, CA, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
PI US 2002164669 A1 20021107
AI US 2001-981876 A1 20011019 (9)
RLI Division of Ser. No. US 2000-621011, filed on 20 Jul 2000, PENDING
PRAI WO 1998-US4482 19980306
US 1997-40162P 19970307 (60)
US 1997-40333P 19970307 (60)

US 1997-38621P 19970307 (60)
US 1997-40161P 19970307 (60)
US 1997-40626P 19970307 (60)
US 1997-40334P 19970307 (60)
US 1997-40336P 19970307 (60)
US 1997-40163P 19970307 (60)
US 1997-47615P 19970523 (60)
US 1997-47600P 19970523 (60)
US 1997-47597P 19970523 (60)
US 1997-47502P 19970523 (60)
US 1997-47633P 19970523 (60)
US 1997-47583P 19970523 (60)
US 1997-47617P 19970523 (60)
US 1997-47618P 19970523 (60)
US 1997-47503P 19970523 (60)
US 1997-47592P 19970523 (60)
US 1997-47581P 19970523 (60)
US 1997-47584P 19970523 (60)
US 1997-47500P 19970523 (60)
US 1997-47587P 19970523 (60)
US 1997-47492P 19970523 (60)
US 1997-47598P 19970523 (60)
US 1997-47613P 19970523 (60)
US 1997-47582P 19970523 (60)
US 1997-47596P 19970523 (60)
US 1997-47612P 19970523 (60)
US 1997-47632P 19970523 (60)
US 1997-47601P 19970523 (60)
US 1997-43580P 19970411 (60)
US 1997-43568P 19970411 (60)
US 1997-43314P 19970411 (60)
US 1997-43569P 19970411 (60)
US 1997-43311P 19970411 (60)
US 1997-43671P 19970411 (60)
US 1997-43674P 19970411 (60)
US 1997-43669P 19970411 (60)
US 1997-43312P 19970411 (60)
US 1997-43313P 19970411 (60)
US 1997-43672P 19970411 (60)
US 1997-43315P 19970411 (60)
US 1997-48974P 19970606 (60)
US 1997-56886P 19970822 (60)
US 1997-56877P 19970822 (60)
US 1997-56889P 19970822 (60)
US 1997-56893P 19970822 (60)
US 1997-56630P 19970822 (60)
US 1997-56878P 19970822 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 13983
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and **treating** disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 53 OF 86 USPATFULL on STN
AN 2002:265556 USPATFULL
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria

IN Hultgren, Scott, Ballwin, MO, UNITED STATES
Kuehn, Meta, Berkeley, CA, UNITED STATES
Xu, Zheng, Blue Bell, PA, UNITED STATES
Ogg, Derek, Stockholm, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, UNITED STATES
Kihlberg, Jan, Dalby, SWEDEN
PI US 2002146428 A1 20021010
US 6962791 B2 20051108
AI US 2001-799608 A1 20010307 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, PENDING
Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN
Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED
DT Utility
FS APPLICATION
LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 5621
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 54 OF 86 USPATFULL on STN
AN 2002:174960 USPATFULL
TI Compounds and pharmaceutical compositions for the **treatment** and prophylaxis of bacterial infections
IN Hultgren, Scott, Ballwin, MO, United States
Kuehn, Meta, Berkeley, CA, United States
Xu, Zheng, Blue Bell, PA, United States
Ogg, Derek, Uppsala, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, United States
Kihlberg, Jan, Dalby, SWEDEN
PA Washington University, St. Louis, MO, United States (U.S. corporation)
Siga Pharmaceuticals, Inc., Corvallis, OR, United States (U.S. corporation)
PI US 6420127 B1 20020716
WO 9514028 19950526
AI US 1996-640877 19961010 (8)
WO 1994-US13455 19941118
19961010 PCT 371 date
DT Utility
FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 5398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of

pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 55 OF 86 USPATFULL on STN
AN 2002:129527 USPATFULL
TI Capsular polysaccharide adhesin antigen, preparation, purification and use
IN Pier, Gerald B., Brookline, MA, United States
PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)
PI US 6399066 B1 20020604
AI US 1999-393832 19990910 (9)
RLI Division of Ser. No. US 1994-336688, filed on 7 Nov 1994, now patented, Pat. No. US 5980910 Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, now abandoned Continuation of Ser. No. US 1991-727982, filed on 10 Jul 1991, now abandoned Division of Ser. No. US 1988-250417, filed on 28 Sep 1988, now patented, Pat. No. US 5055455
DT Utility
FS GRANTED
EXNAM Primary Examiner: Graser, Jennifer E.
LREP Wolf, Greenfield and Sacks, P.C.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 845
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 56 OF 86 USPATFULL on STN
AN 2002:126346 USPATFULL
TI COMPOSITIONS INCLUDING GLYCOSAMINOGLYCANS DEGRADING ENZYMES AND USE OF SAME AGAINST SURFACE PROTECTED BACTERIA
IN YACOBY-ZEEVI, ORON, MEITAR, ISRAEL
PI US 2002064858 A1 20020530
US 6423312 B2 20020723
AI US 1998-140888 A1 19980827 (9)
RLI Continuation of Ser. No. US 1998-46475, filed on 25 Mar 1998, PATENTED Continuation-in-part of Ser. No. US 1997-922170, filed on 2 Sep 1997, PATENTED
DT Utility
FS APPLICATION
LREP Sol Steinbein, G. E. Ehrlich Ltd, c/o Anthony Castorina, 2001 Jefferson Davis Highway Ste. 207, Arlington, VA, 22202
CLMN Number of Claims: 41
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of rendering a surface protected bacteria more susceptible to

an anti-bacterial agent effected by subjecting the bacteria to a glycosaminoglycans degrading enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 57 OF 86 USPATFULL on STN
AN 2002:85159 USPATFULL
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, UNITED STATES
Kuehn, Meta, Berkeley, CA, UNITED STATES
Xu, Zheng, Blue Bell, PA, UNITED STATES
Ogg, Derek, Stockholm, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, UNITED STATES
Kihlberg, Jan, Dalby, SWEDEN
PI US 2002045199 A1 20020418
US 6596504 B2 20030722
AI US 2001-799540 A1 20010307 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, PENDING
Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN
Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED
DT Utility
FS APPLICATION
LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404
CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 5601
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 58 OF 86 USPATFULL on STN
AN 2002:60940 USPATFULL
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, UNITED STATES
Kuehn, Meta, Berkeley, CA, UNITED STATES
Xu, Zheng, Blue Bell, PA, UNITED STATES
Ogg, Derek, Stockholm, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, UNITED STATES
Kihlberg, Jan, Dalby, SWEDEN
PI US 2002034774 A1 20020321
US 6548265 B2 20030415
AI US 2001-799576 A1 20010307 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, PENDING
Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994, UNKNOWN
Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED
DT Utility
FS APPLICATION
LREP Teresa Stanek Rea, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404

CLMN Number of Claims: 37
ECL Exemplary Claim: 1
DRWN 25 Drawing Page(s)
LN.CNT 5543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 59 OF 86 USPATFULL on STN
AN 2002:16560 USPATFULL
TI Methods and compositions for inhibiting adhesion by microorganisms
IN Doyle, Ron J., Louisville, KY, UNITED STATES
Cowan, M. M., Cincinnati, OH, UNITED STATES
PI US 2002009436 A1 20020124
AI US 2000-750857 A1 20001229 (9)
PRAI US 1999-173821P 19991230 (60)
DT Utility
FS APPLICATION
LREP MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2655
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed generally to compositions and methods for enzymatic reduction of adhesion by a microorganism to cells, tissues, extracellular matrix, teeth, and/or dental prostheses. The compositions of the invention include pharmaceutical compositions and oral care compositions containing an enzyme that can reduce binding of a microbe to a cell, a tissue, or a surface. Suitable enzymes include a polyphenol oxidase and an asparaginase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 60 OF 86 USPATFULL on STN
AN 2001:170867 USPATFULL
TI Colorimetric glycopolythiophene biosensors
IN Charych, Deborah J., Albony, CA, United States
Myung-Gi-Baek, Ottawa, Canada
PA The Regents of the University of California (U.S. corporation)
PI US 2001026915 A1 20011004
US 6660484 B2 20031209
AI US 2000-734410 A1 20001211 (9)
RLI Continuation-in-part of Ser. No. US 1999-461509, filed on 14 Dec 1999, PENDING Division of Ser. No. US 1996-592724, filed on 26 Jan 1996, GRANTED, Pat. No. US 6001556 Continuation-in-part of Ser. No. US 1993-159927, filed on 30 Nov 1993, ABANDONED Continuation-in-part of Ser. No. US 1992-976697, filed on 13 Nov 1992, ABANDONED Continuation-in-part of Ser. No. US 2000-500295, filed on 8 Feb 2000, PENDING Division of Ser. No. US 1997-920501, filed on 29 Aug 1997, GRANTED, Pat. No. US 6022748 Continuation-in-part of Ser. No. US 1998-103344, filed on 23 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1996-609312, filed on 1 Mar 1996, GRANTED, Pat. No. US 6183772 Continuation-in-part of Ser. No. US 1995-389475, filed on 13 Feb 1995, ABANDONED Continuation-in-part of Ser. No. US 1994-289384, filed on 11 Aug 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-328237, filed on 24 Oct 1994, ABANDONED Continuation-in-part of Ser. No. US 1997-944323, filed on 6 Oct 1997, GRANTED, Pat. No. US 6180135 Division of Ser. No. US 1995-389475, filed on 13 Feb 1995, ABANDONED

Continuation-in-part of Ser. No. US 1998-23898, filed on 13 Feb 1998, PENDING Continuation-in-part of Ser. No. US 1998-33557, filed on 2 Mar 1998, PENDING Continuation-in-part of Ser. No. US 1999-337973, filed on 21 Jun 1999, PENDING

PRAI US 1999-170190P 19991210 (60)
US 1997-50496P 19970623 (60)
US 1997-38383P 19970214 (60)
US 1997-39749P 19970303 (60)
US 1998-90266P 19980622 (60)

DT Utility
FS APPLICATION
LREP MEDLEN & CARROLL, LLP, 220 Montgomery Street, Suite 2200, San Francisco, CA, 94104
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 13 Drawing Page(s)
LN.CNT 2671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions for the direct detection of analytes using observable spectral changes in biopolymeric systems. In particular, the present invention allows for the direct colorimetric detection of analytes using color changes that occur in glycopolythiophene polymer systems in response to selective binding of analytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 61 OF 86 USPATFULL on STN
AN 2000:160793 USPATFULL
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, United States
Kuehn, Meta, Berkeley, CA, United States
Xu, Zheng, Blue Bell, PA, United States
Ogg, Derek, Uppsala, Sweden
Harris, Mark, Uppsala, Sweden
Lepisto , Matti, Lund, Sweden
Kihlberg, Jan, Dalby, Sweden
Jones, Charles Hal, St. Louis, MO, United States
PA SIGA Pharmaceuticals, Inc., New York, NY, United States (U.S. corporation)
Washington University, St. Louis, MO, United States (U.S. corporation)
PI US 6153396 20001128
AI US 1995-465275 19950605 (8)
RLI Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 which is a continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Swartz, Rodney P.
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 29 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 5410
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 62 OF 86 USPATFULL on STN
AN 1999:163678 USPATFULL
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, 1637 Country Hill La., Ballwin, MO, United States
Kuehn, Meta, 7351 Claremont Ave., #2, Berkeley, CA, United States 94705
Xu, Zheng, 887 Village Cir., Blue Bell, PA, United States 19422
Ogg, Derek, Artillerigatan 16B, S-752 37, Uppsala, Sweden
Harris, Mark, Norbykallvagen 2, S-756 45 Uppsala, Sweden
Lepisto , Matti, Flygelvaagen 257, S-224 73 Lund, Sweden
Kihlberg, Jan, Havrevagen 16, S-240 10 Dalby, Sweden
Jones, Charles Hal, 1104 Moorlands Dr., St. Louis, MO, United States 63110
PI US 6001823 19991214
AI US 1995-462436 19950605 (8)
RLI Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 which is a continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 34 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 5409
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 63 OF 86 USPATFULL on STN
AN 1999:159997 USPATFULL
TI Compounds that bind bacterial pili
IN Shekhani, Mohammed Saleh, Madison, WI, United States
Firca, Joseph R., Vernon Hills, IL, United States
Anderson, Byron, Morton Grove, IL, United States
PA Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S. corporation)
PI US 5998381 19991207
AI US 1996-760903 19961206 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Peselev, Elli
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 24
ECL Exemplary Claim: 5
DRWN 23 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 6570
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Diagnostics and **treatments** for bacterial infection are disclosed. The **treatments** prevent bacteria from adhering to host cells by interfering with the binding of the bacteria to cell receptors. Compounds that inhibit bacterial adherence to cells are engineered to be readily modified for best efficacy with different modes of **treatment**. The compounds can be readily modified for use to identify bacteria according to their cell binding specificities.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 64 OF 86 USPATFULL on STN
AN 1999:155456 USPATFULL
TI Proteins involved in the synthesis and assembly of O-antigen in Pseudomonas aeruginosa
IN Lam, Joseph S., Guelph, Canada
Burrows, Lori, Guelph, Canada
Charter, Deborah, Guelph, Canada
de Kievit, Teresa, Guelph, Canada
PA University of Guelph, Guelph, Canada (non-U.S. corporation)
PI US 5994072 19991130
AI US 1997-846762 19970430 (8)
PRAI US 1996-16510P 19960430 (60)
US 1997-39473P 19970227 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Degen, Nancy; Assistant Examiner: Schwartzman, Robert
LREP Merchant & Gould P.C.
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN 66 Drawing Figure(s); 63 Drawing Page(s)
LN.CNT 7459
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel nucleic acid molecules encoding proteins involved in the synthesis and assembly of O-antigen in P. aeruginosa; and novel proteins encoded by the nucleic acid molecules are described. Methods are disclosed for detecting P. aeruginosa in a sample by determining the presence of the proteins or a nucleic acid molecule encoding the proteins in the sample.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 65 OF 86 USPATFULL on STN
AN 1999:141317 USPATFULL
TI Capsular polysaccharide adhesion antigen preparation, purification and use
IN Pier, Gerald B., Brookline, MA, United States
PA Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)
PI US 5980910 19991109
AI US 1994-336688 19941107 (8)
RLI Continuation of Ser. No. US 1993-33756, filed on 18 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-727982, filed on 10 Jul 1991, now abandoned which is a division of Ser. No. US 1988-250417, filed on 28 Sep 1988, now patented, Pat. No. US 5055455
DT Utility
FS Granted
EXNAM Primary Examiner: Chin, Christopher L.; Assistant Examiner: Graser, Jennifer
LREP Wolf, Greenfield & Sacks, P.C.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 66 OF 86 USPATFULL on STN

AN 95:110434 USPATFULL
TI Method for **treating** galabiose-binding bacteria infections
IN Magnusson, Hans G., Lund, Sweden
Kihlberg, Jan O., Malmo,both of, Sweden
PA Symbicom Aktiebolag, Umea, Sweden (non-U.S. corporation)
PI US 5474986 19951212
WO 9001488 19900222
AI US 1991-689077 19910411 (7)
WO 1989-DK192 19890811
19910411 PCT 371 date
19910411 PCT 102(e) date
PRAI DK 1988-4550 19880812
DT Utility
FS Granted
EXNAM Primary Examiner: Robinson, Douglas W.; Assistant Examiner: Kunz, Gary L.
LREP Cooper, Iver P.
CLMN Number of Claims: 31
ECL Exemplary Claim: 10
DRWN No Drawings
LN.CNT 1802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for **treating** infections caused by galabiose-binding bacteria using galabiose derivatives modified at the 3' and anomeric positions. The galabiose-derivatives and compositions of same are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 67 OF 86 USPATFULL on STN
AN 91:82203 USPATFULL
TI Capsular polysaccharide adhesin antigen, preparation, purification and use
IN Pier, Gerald B., Brookline, MA, United States
PA Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)
PI US 5055455 19911008
AI US 1988-250417 19880928 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Griffin, Ronald W.
LREP Sterne, Kessler, Goldstein & Fox
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 11 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 768
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphyhlococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 68 OF 86 USPATFULL on STN
AN 90:17708 USPATFULL
TI Antibiotic tan-749, its derivatives, production and use thereof
IN Harada, Setsuo, Kawanishi, Japan
Ono, Hideo, Kobe, Japan
Masuya, Hirotomo, Kawabe, Japan
Natsugari, Hideaki, Ashiya, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 4906659 19900306
AI US 1987-129737 19871207 (7)
RLI Continuation-in-part of Ser. No. US 1986-868739, filed on 30 May 1986, now abandoned And a continuation-in-part of Ser. No. US 1986-941208, filed on 12 Dec 1986, now abandoned
PRAI JP 1985-133491 19850618
JP 1985-143711 19850618
JP 1985-291055 19851223
JP 1985-289671 19851227
JP 1986-293879 19861210
JP 1986-311586 19861226
DT Utility
FS Granted
EXNAM Primary Examiner: Wax, Robert A.
LREP Wenderoth, Lind & Ponack
CLMN Number of Claims: 50
ECL Exemplary Claim: 1,50
DRWN 10 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 6501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A compound of the formula ##STR1## wherein R.sup.1 and R.sup.4 are independently amino or an organic residue bonded through nitrogen, R.sup.2 is hydrogen or alkyl which may be substituted, R.sup.3 is hydrogen or a protecting group and R5 is hydroxyl which may be substituted or amino which may be substituted or salts thereof; with the proviso that when R.sup.1 is amino, leucylamino, acetylamino or benzyloxycarbonylamino, R.sup.3 is hydrogen, methyl or 2-tettrahydropyranyl, R.sup.4 is amino, acetylamino or benzyloxycarbonylamino and R.sup.5 is hydroxyl which may be substituted or amino which may be substituted, R.sup.2 is alkyl which may be substituted, has antibacterial activities against drug-resistant bacteria and therefore can be useful as a chemotherapeutic drug for bacterial infections in mammals.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 69 OF 86 USPATFULL on STN
AN 89:94265 USPATFULL
TI Receptor specific proteins and their use in receptor typing
IN Hull, Richard A., Houston, TX, United States
Hull, Sheila I., Houston, TX, United States
Nowicki, Bogdan, Houston, TX, United States
PA Baylor College of Medicine, Houston, TX, United States (U.S. corporation)
PI US 4882425 19891121
AI US 1987-72197 19870709 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Moskowitz, Margaret; Assistant Examiner: Kushan, Jeff
LREP Fulbright & Jaworski
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1040
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described is composition of matter and methods useful for the indentification of blood group antigens. Additionally a kit which can be used to identify and quantify a large number of blood group antigens is disclosed. The composition of matter and the methods can be used to identify antigens on red blood cells, as well as, on tissue samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 70 OF 86 USPATFULL on STN
AN 88:26156 USPATFULL
TI Synthetic vaccine against urinary infections
IN Schmidt, M. Alexander, Palo Alto, CA, United States
O'Hanley, Peter, Palo Alto, CA, United States

Schoolnik, Gary K., Palo Alto, CA, United States
PA Stanford, CA, United States (U.S. corporation)
PI US 4740585 19880426
AI US 1984-635429 19840730 (6)
DCD 20050405
DT Utility
FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Draper, Garnette D.
LREP Ciotti & Murashige, Irell & Manella
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 582
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A vaccine effective in protecting mammals against **urinary tract infections** is prepared from synthetic peptides substantially equivalent to short sequences contained in HU849 pilin conjugated to substantially antigenically neutral carriers or from a CNBrII fragment of HU849 pilin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 71 OF 86 USPATFULL on STN
AN 88:21210 USPATFULL
TI Chemically defined vaccine against urinary infections
IN O'Hanley, Peter, Palo Alto, CA, United States
Schoolnik, Gary K., Palo Alto, CA, United States
Lark, David, Palo Alto, CA, United States
Falkow, Stanley, Seattle, WA, United States
PA The Board of Trustees of the Leland Stanford Junior University, Stanford, CA, United States (U.S. corporation)
PI US 4736017 19880405
AI US 1984-605287 19840430 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Draper, Garnette D.
LREP Ciotti & Murashige, Irell & Manella
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 672
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A vaccine effective in protecting mammals against urinary infections is prepared from purified Gal-Gal pilus proteins or fragments thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 72 OF 86 USPATFULL on STN
AN 88:9749 USPATFULL
TI Vaccine composition for immunization against **urinary tract infection** caused by E. coli
IN Brinton, Jr., Charles C., Pittsburgh, PA, United States
Fusco, Peter C., Pittsburgh, PA, United States
PA Bactex, Inc., Pittsburgh, United States (U.S. corporation)
PI US 4725435 19880216
AI US 1986-875473 19860618 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Kight, John; Assistant Examiner: Draper, Garnette D.
LREP Behr, Omri M.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 449
AB There is provided a vaccine material capable of providing substantial levels of protection against **urinary tract infection** caused by Escherichia coli. The protecting means comprises pili of organisms having pili of the same pilic family as

those on the infecting organism. Protection is given by administering the pili to the subject to be protected.

L6 ANSWER 73 OF 86 USPATFULL on STN
AN 84:33028 USPATFULL
TI Immunization against infection by Escherichia coli
IN Brinton, Charles C., Pittsburgh, PA, United States
PA Bactex, Inc., Pittsburgh, PA, United States (U.S. corporation)
PI US 4454117 19840612
AI US 1982-417464 19820913 (6)
DCD 19971202
RLI Continuation of Ser. No. US 1980-187051, filed on 15 Sep 1980 which is a continuation-in-part of Ser. No. US 1977-854343, filed on 23 Nov 1977, now patented, Pat. No. US 4237115, issued on 2 Dec 1980
DT Utility
FS Granted
EXNAM Primary Examiner: Rosen, Sam
LREP Behr, Omri M.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1,5
DRWN No Drawings
LN.CNT 504
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is provided a vaccine material capable of providing substantial levels of protection against human disease caused by infection with Escherichia coli. The protecting means comprises pili of the infecting organism. The protection is given either by administering the pili directly to the subject to be protected or to a pregnant or lactating female where protection of the newborn is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 74 OF 86 USPATFULL on STN
AN 84:33027 USPATFULL
TI Immunization of humans against enterotoxogenic infection by Escherichia coli
IN Brinton, Charles C., Pittsburgh, PA, United States
PA Bactex, Inc., Pittsburgh, PA, United States (U.S. corporation)
PI US 4454116 19840612
AI US 1980-187051 19800915 (6)
DCD 19971202
RLI Continuation-in-part of Ser. No. US 1977-854343, filed on 23 Nov 1977, now patented, Pat. No. US 4237115
DT Utility
FS Granted
EXNAM Primary Examiner: Hazel, Blondel
LREP Behr, Omri M.
CLMN Number of Claims: 4
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 490
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB There is provided a vaccine material capable of providing substantial levels of protection against human disease caused by infection with Escherichia coli. The protecting means comprises pili of the infecting organism. The protection is given either by administering the pili directly to the subject to be protected or to a pregnant or lactating female where protection of the newborn is desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 75 OF 86 USPATFULL on STN
AN 76:23132 USPATFULL
TI Process for the preparation of xylostasin
IN Horii, Satoshi, Osaka, Japan
Nogami, Ikuo, Kyoto, Japan
Hasegawa, Toru, Kawani, Japan
Yoneda, Masahiko, Uozakinaka, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 3953293 19760427
AI US 1974-493619 19740731 (5)
RLI Division of Ser. No. US 1973-362504, filed on 21 May 1973, now abandoned
PRAI JP 1972-54581 19720531
DT Utility
FS Granted
EXNAM Primary Examiner: Monacell, A. Louis; Assistant Examiner: Wiseman, Thomas G.
LREP Wenderoth, Lind & Ponack
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 425
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A novel aminoglycoside antibiotic, xylostasin, of the nomenclature O-β-D-xylofuranosyl-(1→5)-O-[α-2,6-diamino-2,6-dideoxy-D-glucopyranosyl-(1→4)]-2-deoxystreptamine and its pharmaceutically acceptable acid salts which are effective against infections with bacteria, and a process for producing the antibiotic by cultivating a strain belonging to the genus Bacillus which is capable of producing the antibiotic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 76 OF 86 USPAT2 on STN
AN 2004:221354 USPAT2
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 6926898 B2 20050809
AI US 2001-832929 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Weber, Jon; Assistant Examiner: Robinson, Hope A.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner LLP
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 18544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 77 OF 86 USPAT2 on STN
AN 2003:312278 USPAT2
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S. corporation)
PI US 6905688 B2 20050614
AI US 2001-833118 20010412 (9)
PRAI US 2000-229358P 20000412 (60)

US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Hope A.
LREP Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN 21 Drawing Figure(s); 20 Drawing Page(s)
LN.CNT 16530
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of **treating**, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 78 OF 86 USPAT2 on STN
AN 2003:289203 USPAT2
TI Plant proanthocyanidin extract effective at inhibiting adherence of bacteria with p-type fimbriae to surfaces
IN Howell, Amy B., Hamilton, NJ, United States
Vorsa, Nicholi, Atco, NJ, United States
PA Rutgers, The State University of New Jersey, New Brunswick, NJ, United States (U.S. corporation)
PI US 6720353 B2 20040413
AI US 2003-428063 20030430 (10)
RLI Division of Ser. No. US 1998-145694, filed on 2 Sep 1998, now patented, Pat. No. US 6608102
PRAI US 1997-58307P 19970909 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Solola, Taofiq
LREP Hale and Dorr LLP
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 5 Drawing Figure(s); 11 Drawing Page(s)
LN.CNT 1572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and **treatment** of **urinary tract infections** caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 79 OF 86 USPAT2 on STN
AN 2003:106731 USPAT2
TI **D-mannose** contraceptives
IN Benedict, Dale L., Fayetteville, AR, United States

Benedict, Martha, Fayetteville, AR, United States
PA Biotech Pharmacal, Inc., Fayetteville, AR, United States (U.S. corporation)
PI US 6753319 B2 20040622
AI US 2002-231399 20020829 (10)
PRAI US 2001-315661P 20010829 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Jagoe, Donna
LREP Jackson Walker, LLP, Miller, Mark H., Nash, William B.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns the use of **D-Mannose** to prevent or inhibit uniting of sperm and egg in the conception process. The administration of **D-Mannose** to a female such that the environment of an egg has sufficient **D-Mannose** to inhibit interaction of sperm and the egg and prevent or inhibit conception. **D-Mannose** dosages may be complimentary to other methods of birth control to enhance their effectiveness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 80 OF 86 USPAT2 on STN
AN 2003:37487 USPAT2
TI Secreted protein HODAZ50
IN Ruben, Steven M., Olney, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Fischer, Carrie L., Burke, VA, United States
Soppet, Daniel R., Centreville, VA, United States
Carter, Kenneth C., North Potomac, MD, United States
Bednarik, Daniel P., Columbia, MD, United States
Endress, Gregory A., Potomac, MD, United States
Yu, Guo-Liang, Berkeley, CA, United States
Ni, Jian, Rockville, MD, United States
Feng, Ping, Gaithersburg, MD, United States
Young, Paul E., Gaithersburg, MD, United States
Greene, John M., Gaithersburg, MD, United States
Ferrie, Ann M., Tewksbury, MA, United States
Duan, Roxanne, Bethesda, MD, United States
Hu, Jing-Shan, Sunnyvale, CA, United States
Florence, Kimberly A., Rockville, MD, United States
Olsen, Henrik S., Gaithersburg, MD, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Brewer, Laurie A., St. Paul, MN, United States
Shi, Yanggu, Gaithersburg, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6590075 B2 20030708
AI US 1998-148545 19980904 (9)
PRAI US 1997-40162P 19970307 (60)
US 1997-40333P 19970307 (60)
US 1997-38621P 19970307 (60)
US 1997-40161P 19970307 (60)
US 1997-40626P 19970307 (60)
US 1997-40336P 19970307 (60)
US 1997-40163P 19970307 (60)
US 1997-47615P 19970523 (60)
US 1997-47600P 19970523 (60)
US 1997-47597P 19970523 (60)
US 1997-47502P 19970523 (60)
US 1997-47633P 19970523 (60)
US 1997-47583P 19970523 (60)
US 1997-47617P 19970523 (60)
US 1997-47618P 19970523 (60)
US 1997-47503P 19970523 (60)

US 1997-47592P 19970523 (60)
US 1997-47581P 19970523 (60)
US 1997-47584P 19970523 (60)
US 1997-47500P 19970523 (60)
US 1997-47587P 19970523 (60)
US 1997-47492P 19970523 (60)
US 1997-47598P 19970523 (60)
US 1997-47613P 19970523 (60)
US 1997-47582P 19970523 (60)
US 1997-47612P 19970523 (60)
US 1997-47632P 19970523 (60)
US 1997-47601P 19970523 (60)
US 1997-43580P 19970411 (60)
US 1997-40334P 19970307 (60)
US 1997-47596P 19970523 (60)
US 1997-43311P 19970411 (60)
US 1997-56845P 19970822 (60)
US 1997-56631P 19970822 (60)
US 1997-43568P 19970411 (60)
US 1997-43314P 19970411 (60)
US 1997-43569P 19970411 (60)
US 1997-43671P 19970411 (60)
US 1997-43674P 19970411 (60)
US 1997-43669P 19970411 (60)
US 1997-43312P 19970411 (60)
US 1997-43313P 19970411 (60)
US 1997-43672P 19970411 (60)
US 1997-43315P 19970411 (60)
US 1997-48974P 19970406 (60)
US 1997-56886P 19970822 (60)
US 1997-56877P 19970822 (60)
US 1997-56889P 19970822 (60)
US 1997-56893P 19970822 (60)
US 1997-56630P 19970822 (60)
US 1997-56878P 19970822 (60)
US 1997-56662P 19970822 (60)
US 1997-56872P 19970822 (60)
US 1997-56882P 19970822 (60)
US 1997-56637P 19970822 (60)
US 1997-56903P 19970822 (60)
US 1997-56888P 19970822 (60)
US 1997-56879P 19970822 (60)
US 1997-56880P 19970822 (60)
US 1997-56894P 19970822 (60)
US 1997-56911P 19970822 (60)
US 1997-56636P 19970822 (60)
US 1997-56874P 19970822 (60)
US 1997-56910P 19970822 (60)
US 1997-56864P 19970822 (60)
US 1997-56892P 19970822 (60)
US 1997-47595P 19970523 (60)
US 1997-57761P 19970905 (60)
US 1997-47599P 19970523 (60)
US 1997-47588P 19970523 (60)
US 1997-47585P 19970523 (60)
US 1997-47586P 19970523 (60)
US 1997-47590P 19970523 (60)
US 1997-47594P 19970523 (60)
US 1997-47589P 19970523 (60)
US 1997-47593P 19970523 (60)
US 1997-47614P 19970523 (60)
US 1997-43578P 19970411 (60)
US 1997-43576P 19970411 (60)
US 1997-47501P 19970523 (60)
US 1997-43670P 19970411 (60)
US 1997-56632P 19970822 (60)
US 1997-56664P 19970822 (60)
US 1997-56876P 19970822 (60)
US 1997-56881P 19970822 (60)

US 1997-56909P 19970822 (60)
US 1997-56875P 19970822 (60)
US 1997-56862P 19970822 (60)
US 1997-56887P 19970822 (60)
US 1997-56908P 19970822 (60)
US 1997-48964P 19970606 (60)
US 1997-57650P 19970905 (60)
US 1997-56884P 19970822 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Carlson, Karen Cochrane; Assistant Examiner: Robinson, Hope A.
LREP Human Genome Sciences, Inc.
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 13365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and **treating** disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 81 OF 86 USPAT2 on STN
AN 2002:265556 USPAT2
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, UNITED STATES
Kuehn, Meta, Berkeley, CA, UNITED STATES
Xu, Zheng, Blue Bell, PA, UNITED STATES
Ogg, Derek, Uppsala, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, UNITED STATES
Kihlberg, Jan, Dalby, SWEDEN
PA Washington University, St. Louis, MO, UNITED STATES (U.S. corporation)
Siga Pharmaceuticals, Inc., New York, NY, UNITED STATES (U.S. corporation)
PI US 6962791 B2 20051108
AI US 2001-799608 20010307 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, Pat. No. US 6420127 Division of Ser. No. WO 1994-US13455, filed on 8 Nov 1994, PENDING Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, ABANDONED
DT Utility
FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 5365
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 82 OF 86 USPAT2 on STN
AN 2002:126346 USPAT2
TI Compositions including glycosaminoglycans degrading enzymes and use of same against surface protected bacteria
IN Yacoby-Zeevi, Oron, Meitar, ISRAEL
PA Insight Strategy & Marketing Ltd., Rehovot, ISRAEL (non-U.S. corporation)
PI US 6423312 B2 20020723
AI US 1998-140888 19980827 (9)
RLI Continuation-in-part of Ser. No. US 1998-46475, filed on 25 Mar 1998, now patented, Pat. No. US 6153187 Continuation-in-part of Ser. No. US 1997-922170, filed on 2 Sep 1997, now patented, Pat. No. US 5968822
DT Utility
FS GRANTED
EXNAM Primary Examiner: Prout, Rebecca E.
LREP G.E. Ehrlich Ltd.
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 7 Drawing Page(s)
LN.CNT 1120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of rendering a surface protected bacteria more susceptible to an anti-bacterial agent effected by subjecting the bacteria to a glycosaminoglycans degrading enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 83 OF 86 USPAT2 on STN
AN 2002:85159 USPAT2
TI **Treatment** of prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, United States
Kuehn, Meta, Berkeley, CA, United States
Xu, Zheng, Blue Bell, PA, United States
Ogg, Derek, Uppsala, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, United States
Kihlberg, Jan, Dalby, SWEDEN
PA Washington University, St. Louis, MO, United States (U.S. corporation)
SIGA Pharmaceuticals, Inc., New York, NY, United States (U.S. corporation)
PI US 6596504 B2 20030722
AI US 2001-799540 20010307 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996 Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 24 Drawing Page(s)
LN.CNT 5179
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 84 OF 86 USPAT2 on STN
AN 2002:60940 USPAT2
TI **Treatment** or prophylaxis of diseases caused by pilus-forming bacteria
IN Hultgren, Scott, Ballwin, MO, United States
Kuehn, Meta, Berkeley, CA, United States
Xu, Zheng, Blue Bell, PA, United States
Ogg, Derek, Uppsala, SWEDEN
Harris, Mark, Uppsala, SWEDEN
Lepisto, Matti, Lund, SWEDEN
Jones, Charles Hal, Saint Louis, MO, United States
Kihlberg, Jan, Dalby, SWEDEN
PA Washington University, St. Louis, MO, United States (U.S. corporation)
Siga Pharmaceuticals, Inc., Corvallis, OR, United States (U.S. corporation)
PI US 6548265 B2 20030415
AI US 2001-799576 20010307 (9)
RLI Division of Ser. No. US 1996-640877, filed on 10 Oct 1996, now patented, Pat. No. US 6420127 Division of Ser. No. WO 1994-US13455, filed on 18 Nov 1994 Continuation-in-part of Ser. No. US 1993-154035, filed on 18 Nov 1993, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Swartz, Rodney P
LREP Burns, Doane, Swecker & Mathis, L.L.P.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 35 Drawing Figure(s); 25 Drawing Page(s)
LN.CNT 5270
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel methods for the **treatment** and/or prophylaxis of diseases caused by tissue-adhering bacteria are disclosed. By interacting with periplasmic molecular chaperones it is achieved that the assembly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished. Also disclosed are methods for screening for drugs as well as methods for the de novo design of such drugs, methods which rely on novel computer drug modelling methods involving an approximative calculation of binding free energy between macromolecules. Finally, novel pyranosides which are believed to be capable of interacting with periplasmic molecular chaperones are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 85 OF 86 USPAT2 on STN
AN 2001:170867 USPAT2
TI Colorimetric glycopolythiophene biosensors
IN Charych, Deborah J., Albony, CA, United States
Baek, Myung-Gi, Ottawa, CANADA
PA Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6660484 B2 20031209
AI US 2000-734410 20001211 (9)
RLI Continuation-in-part of Ser. No. US 1999-461509, filed on 14 Dec 1999, now patented, Pat. No. US 6395561 Division of Ser. No. US 1996-592724, filed on 26 Jan 1996, now patented, Pat. No. US 6001556, issued on 14 Dec 1999 Continuation-in-part of Ser. No. US 1993-159927, filed on 30 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1992-976697, filed on 13 Nov 1992, now abandoned Continuation-in-part of Ser. No. US 2000-500295, filed on 8 Feb 2000 Division of Ser. No. US 1997-920501, filed on 29 Aug 1997, now patented, Pat. No. US 6022748, issued on 8 Feb 2000 Continuation-in-part of Ser. No. US 1998-103344, filed on 23 Jun 1998 Continuation-in-part of Ser. No. US 1996-609312, filed on 1 Mar 1996, now patented, Pat. No. US 6183772 Continuation-in-part of Ser. No. US 1995-389475, filed on 13 Feb 1995, now abandoned Continuation-in-part of Ser. No. US 1994-289384, filed on 11 Aug 1994, now abandoned Continuation-in-part of Ser. No. US 1994-328237, filed on 24 Oct 1994, now abandoned Continuation-in-part of Ser. No. US 1997-944323, filed on

6 Oct 1997, now patented, Pat. No. US 6180135 Division of Ser. No. US 389475 Continuation-in-part of Ser. No. US 289384 Continuation-in-part of Ser. No. US 328237 Continuation-in-part of Ser. No. US 1998-23898, filed on 13 Feb 1998 Continuation-in-part of Ser. No. US 1998-33557, filed on 2 Mar 1998 Continuation-in-part of Ser. No. US 1999-337973, filed on 21 Jun 1999, now patented, Pat. No. US 6306598

PRAI US 1999-170190P 19991210 (60)
US 1998-90266P 19980622 (60)
US 1997-50496P 19970623 (60)
US 1997-38383P 19970214 (60)
US 1997-39749P 19970303 (60)

DT Utility
FS GRANTED
EXNAM Primary Examiner: Housel, James; Assistant Examiner: Brown, Stacy S.
LREP Hedlen & Carroll, LLP
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN 13 Drawing Figure(s); 13 Drawing Page(s)
LN.CNT 2974
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to methods and compositions for the direct detection of analytes using observable spectral changes in biopolymeric systems. In particular, the present invention allows for the direct colorimetric detection of analytes using color changes that occur in glycopolythiophene polymer systems in response to selective binding of analytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 86 OF 86 WPINDEX COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-570523 [55] WPINDEX
DNC C2004-208289
TI Use of **D-mannose** for maintenance of urinary tract health in the face of infection e.g. E. Coli infection.
DC B03 B04
IN ONEAL, J; WHITE, G
PA (ONEA-I) ONEAL J; (WHIT-I) WHITE G
CYC 1
PI US 2004147459 A1 20040729 (200455)* 6
ADT US 2004147459 A1 Provisional US 2002-420696P 20021023, US 2003-691423 20031022
PRAI US 2002-420696P 20021023; US 2003-691423 20031022
AN 2004-570523 [55] WPINDEX
AB US2004147459 A UPAB: 20040826
NOVELTY - Maintenance of urinary tract health in the face of infection involves administering a dosage of 1 - 2 teaspoons of D-**mannose** three times a day with meals for 1 - 2 weeks or until the symptoms subside.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a composition comprising a therapeutic dosage of **D-mannose** and a therapeutic dosage of at least one of an extract of Crataeva nurvala, willow bark or pollen extract simultaneously with D-**mannose**.

ACTIVITY - Uropathic; Antimicrobial.

MECHANISM OF ACTION - E. coli urethral epithelial cell attachment inhibitor.

USE - For maintaining urinary tract health in the face of infection; in combination with a **capsule** containing herbs that affect the urinary tract; and for dealing with a **urinary tract infection** (all claimed). The **urinary tract infection** include E. coli infection.

ADVANTAGE - The use of **D-mannose** in the maintenance of urinary tract health in the face of infection and in the **treatment** of **urinary tract infection** preferentially provides attachment of E. coli fimbriae to the administered **D-mannose** present in the urine, rather than attachment to **D-mannose** in the epithelial cells of the urinary tract. This results in the E. coli bacteria surrounded by the molecules of **D-mannose** and promotes their natural elimination by

mechanical and not pharmacological action. The few remaining bacteria can then be better handled by the body's natural defenses, the white blood cells. Mannose can not be broken down in the body, and thus is safe for diabetics, pregnant women and the elderly, and is virtually free from the risk of overdose The method does not involve the use of antibiotics and hence avoids the side effects and resistant stain development associated with them. The administration regimen provides a quantity of mannose sufficient to remove a majority of E/ coli in the urinary tract, while improving the ease of use and compliance. The dosages are effective in doctor-run trials.
Dwg.0/3

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	295.45	295.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

FILE 'CAPLUS' ENTERED AT 09:36:58 ON 30 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 30 Jan 2006 VOL 144 ISS 6
FILE LAST UPDATED: 29 Jan 2006 (20060129/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s Oneal Joseph/AU
L8 1 ONEAL JOSEPH/AU

=> dis l8 bib abs

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:612489 CAPLUS
DN 141:117126
TI Method and composition for maintaining urinary tract health in the face of infections
IN **Oneal, Joseph**; White, Gary
PA USA
SO U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be

of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala , white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

=> s White Gary/AU
L9 8 WHITE GARY/AU

=> dis l9 1-8 bib abs

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:612489 CAPLUS
DN 141:117126
TI Method and composition for maintaining urinary tract health in the face of infections
IN Oneal, Joseph; **White, Gary**
PA USA
SO U.S. Pat. Appl. Publ., 6 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004147459	A1	20040729	US 2003-691423	20031022
PRAI US 2002-420696P	P	20021023		

AB The sugar mannose has been used to maintain urinary tract health in the face of Escherichia coli infections. An optimal dose is disclosed to be of one tsp (two grams) three times a day for one to two weeks or until symptoms subside. The maintenance dosage for prophylaxis is one-half tsp (1 g) 1 to two times per day. Children's dosages are cut in half. For women who experience UTIs after sexual relations, one tsp is taken an hour prior to intimate relations and an addnl. one tsp immediately afterwards. It is further disclosed to use any of an extract of Crataeva nurvala , white willow bark, and pollen extract in conjunction with the mannose to provide further effect.

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:493491 CAPLUS
DN 141:39547
TI Laminated siding panels having preselected colors
IN Regelski, Joe R.; Levendusky, Thomas L.; **White, Gary**
PA USA
SO U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004115398	A1	20040617	US 2002-318427	20021213
US 2005003154	A1	20050106	US 2004-817604	20040402
PRAI US 2002-318427	A2	20021213		

AB A process for making laminated plastic panels suitable for use on buildings and having a preselected color, comprises the steps of: forming a plastic sheet at an elevated temperature, the formed sheet having an exterior surface portion; overlaying the exterior surface portion of the formed sheet with a coloring sheet having a preselected color and comprising a polymeric binder and pigment particles, said binder comprising a plastisol; and laminating the coloring sheet to the formed sheet by means of a roll continuously contacting the coloring sheet, said formed sheet maintaining a sufficient temperature while pressure is applied to the roll to bond said coloring sheet to said formed sheet, thereby to produce a laminated plastic panel having a preselected color. The coloring sheet

preferably comprises a vinyl resin plastisol and pigment particles. Both the formed sheet and the vinyl resin in the plastisol preferably comprise polyvinyl chloride (PVC). Use of the coloring sheet enables color changes to be accomplished quickly and inexpensively so that manufacturers are able to maintain smaller inventories of the finished product while still satisfying customer needs.

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:8747 CAPLUS
TI Episodic blockade of cranial nerve VIII provokes asymmetric changes in lobule X of the rat
AU Saxon, Dale W.; **White, Gary**
CS Evansville Center for Medical Education, Department of Anatomy and Cell Biology, Indiana University School of Medicine, Evansville, IN, 47712, USA
SO Brain Research (2004), 997(2), 165-175
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
AB Although debilitating syndromes like Meniere's disease are in part characterized by recurrent or episodic vestibular disturbance the study of episodic vestibular disruption has only recently been possible with the introduction of a new model utilizing tetrodotoxin (TTX). In the present study, serial unilateral transtympanic administration of TTX produced behavioral symptoms indicative of transient vestibular disruption and novel patterns of Fos activity in the brainstem and cerebellum. Following two or three serial injections of TTX and a final survival time of 2 h, Fos immunocytochem. revealed a distinct pattern of labeling in the brainstem that differed temporally from that observed following a single unilateral TTX injection. Specifically there was protracted expression of Fos in the β subdivision of the inferior olive (IO) on the side ipsilateral to TTX treatment. In the cerebellum, the hallmark of episodic vestibular blockade was an asym. pattern of Fos labeling that involved all three layers of the cortex. In particular, there was prominent Fos labeling of Purkinje cells in the contra-TTX half of lobule X. In view of the fact that Fos labeling is not found in Purkinje cells following a single transient event or following peripheral vestibular ablation, it is suggested that Fos expression in Purkinje cells is a unique feature of episodic vestibular disruption and may represent a novel plastic response by a select population of Purkinje cells to episodic functional deafferentation.
RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:526796 CAPLUS
DN 139:288865
TI Novel Kaposi's sarcoma-associated herpesvirus homolog in baboons
AU Whitby, Denise; Stossel, Andrea; Gamache, Christine; Papin, James; Bosch, Marnix; Smith, Anne; Kedes, Dean H.; **White, Gary**; Kennedy, Ronald; Dittmer, Dirk P.
CS Viral Epidemiology Section, AIDS Vaccine Program, National Cancer Institute-Frederick, SAIC-Frederick, Frederick, MD, 21702, USA
SO Journal of Virology (2003), 77(14), 8159-8165
CODEN: JOVIAM; ISSN: 0022-538X
PB American Society for Microbiology
DT Journal
LA English
AB Kaposi's sarcoma (KS) and lymphoproliferative diseases induced by KS-associated herpesvirus (KSHV/human herpesvirus 8) cause substantial morbidity and mortality in human immunodeficiency virus-infected individuals. To understand KSHV biol. it is useful to investigate closely related rhadinoviruses naturally occurring in nonhuman primates. Here we report evidence for a novel KSHV homolog in captive baboon species (Papio anubis and other). Using degenerate PCR we identified a novel rhadinovirus, PapRV2, that has substantial sequence identity to 2 essential KSHV genes, the viral polymerase and thymidylate synthase. A subset of animals exhibited detectable PapRV2 viral load in peripheral blood mononuclear cells. Extensive serol. anal. of nearly 200 animals in

the colony demonstrated that the majority carried cross-reacting antibodies that recognize KSHV or macaque rhadinovirus antigens. Seroreactivity increased with age, similar to the age-specific prevalence of KSHV in the human population. This establishes baboons as a novel resource to investigate rhadinovirus biol., which can be developed into an animal model system for KSHV-associated human diseases, vaccine development, and therapy evaluation.

RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:855405 CAPLUS
DN 134:159973
TI Simian foamy virus infections in a baboon breeding colony
AU Blewett, Earl L.; Black, Darla H.; Lerche, Nicholas W.; **White, Gary**; Eberle, R.
CS College of Osteopathic Medicine, Oklahoma State University, Tulsa, OK, 74107, USA
SO Virology (2000), 278(1), 183-193
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic Press
DT Journal
LA English
AB The prevalence, transmission, and variation of simian foamy viruses (SFVs) in baboons was investigated. Over 95% of adult baboons in the breeding colony as well as recently imported adult animals had high titers of anti-SFV serum IgG. Maternal antibody was detectable in infants' serum up to 6 mo of age. Approx. 30% of infants in breeding harems experienced SFV infections by 1 yr of age. Shedding of SFV in oral secretions was common, with 13% of samples from normal adult animals and 35% from immunosuppressed animals containing infectious SFV. SFV was isolated from three baboon subspecies (olive, yellow, and chacma baboons) and sequences from both the pol and the LTR regions of the provirus were amplified by PCR and sequenced. Phylogenetic anal. indicated that all baboon isolates formed a single lineage distinct from SFVs of other African monkey species. Within the baboon SFV lineage, two distinct clades were apparent, which consisted of isolates from yellow and olive baboons and isolates from chacma baboons. Competition ELISAs indicated that, while SFV isolates of these two groups were very closely related, antigenic differences do exist between them. SFV isolates from a drill and a mandrill were distinct from baboon SFV isolates, both genetically and antigenically. (c) 2000 Academic Press.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1998:813451 CAPLUS
DN 130:174798
TI Optical characterization of organic nonlinear optical crystals irradiated with MeV protons, an electron paramagnetic resonance study
AU Darwish, A. M.; Thompson, Tommy; Williams, Alton; Bhat, Kamala; Thompson, James; Chelette, Kelly; LaFitte, Shane; Hyde, Wayne; **White, Gary**; Glass, Gary A.; Wang, Yongqiang
CS Center for nonlinear optics and materials, Physics Department, Alabama A&M University, Normal, AL, 35867, USA
SO Proceedings of SPIE-The International Society for Optical Engineering (1998), 3470(Photorefractive Fiber and Crystal Devices: Materials, Optical Properties, and Applications IV), 152-161
CODEN: PSISDG; ISSN: 0277-786X
PB SPIE-The International Society for Optical Engineering
DT Journal
LA English
AB In processes of obtaining a new NLO materials, modifying and enhancing the existing materials, various aromatic compds. were synthesized with the intent of comparing their nonlinear optical properties Different techniques were used to characterize the proton-irradiated N-isobutyl-4-methyl-6-nitro-2-quinolinamine sample. From the ESR measurements: the spin concentration seemed to increase significantly when the proton beam increased from 0 to 2.2 MeV and then the spin concentration starts decreasing up to 3 MeV. The EPR signal

for N- iso-Bu was singlet up to 1.8 MeV then split into doublet around 2 MeV, then triplet around 2.2 and then returned again to a weak singlet around 3 MeV. Using LB film for these samples, the SH is maximum for the 2.2 MeV-irradiated-sample. FTIR anal. also shows a dramatic increase in transmission in different bands of the spectra. Due to higher energy proton irradiation, a high significant improvement in the nonlinear characteristics of the sample was observed A theor. interpretation for the effect of the proton irradiation enhancement of the nonlinearity of these will be presented as well.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1981:578370 CAPLUS
DN 95:178370
TI Narrow-band linearly scannable infrared lasing between 1.09 and 1.12 μm in the dye DNDTPC perchlorate
AU **White, Gary**; Pruett, J. Gary
CS Dep. Chem., Univ. Pennsylvania, Philadelphia, PA, 19104, USA
SO Optics Letters (1981), 6(10), 473-4
CODEN: OPLEDP; ISSN: 0146-9592
DT Journal
LA English
AB A grazing-incidence grating-tuned oscillator followed by 2 amplifier stage was used to generate 0.2-cm-1 bandwidth scannable IR radiation between 1.09 and 1.12 μm in 3,3'-diethyl-9,11,15,17-dineopentylene-(6,7,7',7'-dibenzo)thiapentacarbocyanine perchlorate (DNDTPC). When the radiation was pumped with 400-mJ 10-ns pulses from a Nd:YAG laser, the output-pulse energy was .apprx.20 mJ at the peak of the tuning curve.

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:176465 CAPLUS
DN 88:176465
TI Health hazard evaluation determination report number 76-94-406, Westinghouse Electric Corporation, Large Power Transformer Division, Muncie, Indiana
AU Hervin, Raymond L.; Smith, Alexander Blair; **White, Gary**
CS Natl. Inst. Occup. Saf. Health, Cincinnati, OH, USA
SO U. S. NTIS, PB Rep. (1977), PB-273722, 19 pp. Avail.: NTIS
From: Gov. Rep. Announce. Index (U. S.) 1978, 78(3), 65
CODEN: XPBRCA; ISSN: 0099-8583
DT Report
LA English
AB Environmental air sampling and medical evaluation concluded that employees' exposure to airborne total nuisance particulates, oil mists, and organic vapors did not pose a health hazard at the concentration measured. The majority of the 20 affected employees gave a history of apparent dermatitis with the oil which is adherent to surfaces of the transformer as it is assembled. The contention that the transformer oil may contain additives which could be responsible for the apparent toxic manifestations of the oil was not borne out by the investigation. Recommendations are made to alleviate dermatitis problems caused by direct contact with the oil.

=> dis hist

(FILE 'HOME' ENTERED AT 09:23:37 ON 30 JAN 2006)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, JICST-EPLUS, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, MEDLINE, BIOSIS, EMBASE' ENTERED AT 09:24:02 ON 30 JAN 2006

L1 118295 S URINARY(A)TRACT(A)INFECT?
L2 42971 S L1 AND TREAT?
L3 142 S L2 AND D-MANNOSE
L4 5 S L3 AND (CRATAEVA OR WILLOW OR POLLEN)
L5 7 S L3 AND (CRATAVIN OR SALICIN)
L6 86 S L3 AND (CAPSULE OR POWDER)

L7 1 S L3 AND LUPEOL

FILE 'CAPLUS' ENTERED AT 09:36:58 ON 30 JAN 2006
L8 1 S ONEAL JOSEPH/AU
L9 8 S WHITE GARY/AU